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Dust mite has been one of the major causes of allergic diseases and asthma in the 
world. The body parts and faeces of dust mites contain high amount of allergenic 
proteins that can cause allergic reactions (Tovey et al., 1981). An allergic reaction 
requires the cross-linking of IgE antibodies bound on the surface of the mast cells by 
environmental allergenic molecules, and which leads to the release of pro-
inflammatory mediators that causes allergy symptoms. So far, the basis of interaction 
between allergen and IgE antibodies are not well understood.  Hence, structural 
studies of allergens and their epitopes involved in the interaction with IgE are 
extremely important in order to understand the characteristics of an allergen as well as 
to develop hypoallergenic molecules for specific allergen immunotherapy.  
  
 In this thesis, we would like to describe a detailed structural study of Der f 13, a 
group 13 allergen from dust mite Dermatophagoides farinae by using Nuclear 
Magnetic Resonance spectroscopy as well as IgE epitope mapping of the allergen and 
development of a hypoallergenic molecule as potential vaccine for immunotherapy. 
High-resolution solution structure of Der f 13 was solved and was found to be highly 
similar to homologous human fatty acid binding proteins (FABP). Although human 
FABPs are highly similar to Der f 13 in terms of amino acid sequence and structure, 
they do not bind to IgE or elicit any allergic reaction. Sequence alignment with human 
FABP has revealed several unique surface charged residues on Der f 13 that may be 
involved in IgE binding. Epitope residues have been confirmed by using site-directed 
mutagenesis and IgE binding assays and mapped to 4 charged residues Glu-41, Lys-
63, Lys-91 and Lys-103. The side chains of these four residues are highly exposed on 
 x 
the surface of the protein and located on two distinct sites at the opposite surface of 
the protein. A triple mutant 3A (E41A_K63A_K91A) has been generated and shown 
to have a significantly lower IgE binding and reduced skin prick reactivity. The 3A 
mutant also showed similar PBMC proliferation induction as wild type Der f 13 and is 
able to stimulate release of Th1 cytokines while at the same time reducing the 
secretion of Th2 cytokines. Although the IgE epitopes of 3A mutant have been 
removed, it is still able to stimulate production of mouse blocking IgG antibodies that 
are able to inhibit the binding of patients’ sera IgE to wild type Der f 13. These 
findings indicate that 3A mutant is a good hypoallergen candidate that can be used for 
vaccine immunotherapy of Der f 13 allergy. Our observations also implied that 
surface charged residues might play important role in IgE binding and thus allergenic 
properties of allergens in general. 
 
Structural characterization of an additional allergen Blo t 5, from Blomia 
tropicalis has also been carried out using circular dichroism (CD) and NMR 
spectroscopy. Blo t 5 is found to be comprised of mainly α-helices in its secondary 
structure as observed in CD experiments. The backbone chemical shifts of Blo t 5 
have also been assigned using 3D triple resonances NMR experiments. Three α-
helices separated by tight turns were observed in the chemical shift index (CSI) plot. 
CSI has also revealed that the N-terminal region of Blo t 5 may be disordered and 
contain no secondary structures.  
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Chapter 1: Introduction 
1.1 Allergy 
1.1.1 Allergy: An Introduction 
 
Allergy is an immune disease when a predisposed allergic individual shows 
increased sensitivity and abnormal immune response to foreign substances, which are 
normally harmless to non-allergic patients. In a healthy individual, the immune 
system plays a delicate role to balance the maximum protection from the harmful 
invasion of foreign infection, while at the same time minimizing over-reaction against 
self-antigens or non-harmful foreign substances. If this balance is not maintained, it 
could lead to immune system disorders term as ‘Hypersensitivity’. Hypersensitivity 
disorders include autoimmune disorders, in which immune system is targeted against 
self-antigens, as well as diseases that result in uncontrolled reaction against non-
harmful environmental proteins (allergens) and microbes (Abbas and Lichtman, 
2003). Hypersensitivity can be classified in 5 different types based on the pathologic 
immune mechanisms and the components involved. Allergy is synonymous to the 
term ‘immediate hypersensitivity type I’, which is an immunoglobulin E, IgE-
mediated immune response against foreign allergenic molecules. 
 
Atopy is often a term used to describe IgE-mediated diseases. An atopic 
patient is characterized by a hereditary predisposition to produce specific IgE 
antibodies against environmental allergens and to develop strong immediate allergic 
responses (Kay, 2001 and Abbas and Lichtman., 2003). Following the interaction 
between allergens and specific IgE bound on the surface of mast cells or basophils, 
pro-inflammatory mediators such as histamine and leukotrienes will be released, 
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triggering clinical expression of the diseases such as asthma, atopic eczema and 
allergic rhinitis (Kay, 2001). Atopic status is usually demonstrated with a positive 
skin prick test or elevated levels of specific serum IgE to the common allergens.  
 
 Substances that trigger and cause allergic reaction are commonly known as 
allergens. Allergens are normally soluble proteins and they can be found at common 
sources such as house dust mites, pollens, cats, nuts, bee venom and many more. 
Allergens react with specific IgE antibodies, and when such antibodies are bound to 
its receptor Fcε type I, it will trigger the release of pro-inflammatory mediators 
resulting in allergic reaction. Majority of the allergens are involved in the primary 
sensitization and the isotype switching to IgE synthesis. Generally, the sources of 
allergens can be categorized into few major groups, such as pollen, mite, animal, 
fungal, insect and food. Pollen allergens include those from grass such as rye grass 
Lolium perenne and Timothy grass Phleum pratense; as well as those from tree 
pollens such as birch (Betula verrucosa) and olive tree (Olea europaea) (Cromwell, 
1997). The sources of mite allergen include house dust mites Dermatophagoides 
pteronyssinus and Dermatophagoides farinae and storage mite Blomia tropicalis 
remain as one of the main causes of allergy and asthma in the world (Arlian et al., 
2001). Animal allergens come from a wide range of mammals such as cats (Felis 
domesticus), dogs (Canis familiaris), mice (Mus muscalaris), horses (Equus caballus) 
and cows (Bos domesticus). Several genera are implicated as major fungal allergen 
sources comprising Aspergillus, Cladosporium, Alternaria, Penicillium and Fusarium 
(Cromwell, 1997). Honey bee (Apis mellifera) venom and cockroaches (Blatella 
germanica and Periplaneta americana) are the main contributors of insect allergens 
(Arruda et al., 2001). Food allergens include a wider range of sources such as shrimps 
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(Penaeus aztecus), chicken egg white, peanuts (Arachis hypogaea), cow milk and 
meat.   
 
 In the last two decades, the incidences of allergy and asthma have increased 
tremendously worldwide. A recent survey in United States has shown that 54.3% of 
their population had positive skin prick test reaction to one or more allergens tested, 
with an average of an individual reacting to 3 or 4 allergens tested (Arbes et al., 
2005). These figures are alarming as the numbers are already an underestimation as 
only 10 crude allergens were used in this study. According to survey by World Health 
Organization (WHO), there are 15-20 million asthma patients in India alone. A recent 
study in Singapore reported about one in five of children of 2 years old suffers from 
eczema and/or asthma (Tan et al., 2005). Allergy complications not only present a 
major health problem but also give rise to significant financial loss attributed to 
allergy, with around SGD$54 million spent per year in Singapore by asthmatic 
patients (Chew et al., 1999).   
 
 Most of the clinical treatment for allergic diseases has been used to alleviate 
the symptoms and to suppress the allergic inflammation. For examples, common 
treatment for allergic rhinitis is through antihistamines drugs, anticholinergic agents 
or topical corticosteroids (Kay, 2001). Atopic dermatitis is normally treated similarly 
with topical therapy, antihistamines and corticosteroids to control and suppress 
inflammation of the affected site (Roos et al., 2004). Anti asthmatic drugs such as 
short- and long-acting β2-agonists such as salbutamol and salmeterol respectively, 
remain of fundamental importance in the treatment to relieve asthma symptoms and 
maintenance therapy (Kon et al., 1997). However, such pharmacological treatment 
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can only relieve the symptoms, but only allergen-specific immunotherapy can reverse 
the course of the disease and provide protection against progression of allergic 
diseases (Valenta, 2002 and Niederberger et al., 2004).      
 
 
1.1.2 Mechanism of allergy 
 
An allergic reaction would require at least three components, which are 
allergen, IgE and at least one type of effector cells such as mast cells, basophils or 
eosinophils (Abbas and Lichtman, 2003). However, the immune system requires other 
cellular members such as antigen presenting cells (APC) and lymphocyte cells for 
initiation and regulation of allergic reaction and disease progression. When an 
allergen enters through epithelia, it will be captured by APC such as dendritic cells or 
cutaneous Langerhans’ cells and presented as T-cell peptide to CD4+ T cells in a 
major histocompatibility complex MHC class II-restricted manner (Abbas and 
Lichtman, 2003 and Kay, 2001). CD4+ cells will be primed to differentiate into T 
helper 2 cells (Th2) and releasing Th2-type cytokines such as IL-4, IL-5, IL-9 and IL-
13 (Kay, 2001).  
 
The recognition of an antigen by T-cells requires presentation of the antigen 
by the APC in the form of peptide fragments. These peptides, which contain T-cell 
epitopes, will be loaded onto the MHC and the peptide-MHC complexes will be 
displayed for recognition by T-cells. There are two classes of MHC molecules, with 
class I MHC presents the peptides to the CD8+ cytolytic T cells while the class II 
MHC presents the peptides to the CD4+ helper T cells. The class II MHC-peptide 
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complex will be recognized by the T cell receptor (TCR) on the surface of the T cells. 
APCs that commonly initiate helper T cells are the dendritic cells, macrophages and B 
lymphocyte cells. Dendritic cells and cutaneous Langerhans cells have been 
implicated in asthma and eczema respectively by presenting allergens in a MHC class 
II manner to Th2 cells (Kay, 2001).  
 
Upon recognition of the MHC-peptide complexes, an array of cytokines will 
be released by the Th2 cells. Th2 cells and its cytokines play an integral role in 
controlling and intensifying an allergic reaction by increasing the production of IgE 
antibodies and by increasing the development of inflammation cells such as mast 
cells, basophils and eosinophils (see Figure 1.1 for illustration). Interleukins IL-4 and 
IL-13 particularly promote B cells to undergo class switching of constant region of 
immunoglobulin heavy chain to Fcε to produce IgE class antibodies, instead of other 
class of antibodies (Valenta, 2002). IL-4 and IL-9 are involved in elevating the 
development of mast cells, the key effector cells in releasing inflammation mediators 
(Kay, 2001). IL-13 plays a key role in mediating airway hyper-responsiveness (Wills-
Karp et al., 1998) while the expansion and accumulation of eosinophils and basophils 
are induced by IL-4, IL-5, IL-9 and IL-13 (Kay, 2001). The cytokines secreted each 
by Th1 or Th2 cells were shown to act as autocrine growth factors to promote the 
proliferation of these cells, and at the same time act as inhibitor for the growth of the 
cells of the opposite type (Liew, 2002; Gajewski and Fitch, 1988; Fernandez-Botran 
et al., 1988). IL-4 would induce the growth of Th2 cells, but at the same time would 
inhibit the proliferation of Th1 cells. In contrast, IFN-γ, a cytokine released by Th1 
subset of cells, is able to promote the expansion of Th1 cells but inhibit the 
proliferation of Th2 cells.  
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Circulating IgE antibodies bind to its receptor via the constant region, Fcε, on 
heavy chain. Cross-linking of the high affinity receptor, FcεRI on the mast cells or 
basophils by allergen-bound IgE would release inflammatory mediators such as 
histamine, leukotrienes and lipid mediators (Turner and Kinet, 1999; Kay, 2001 and 
Valenta, 2002). This receptor also exists on the surface of APC such as dendritic cells 
where it can assist in IgE-mediated trapping of the allergen, enabling the allergen to 
be presented to the T cells in an IgE-mediated pathway (Stingl and Maurer, 1997). 
Crystal structure of the FcεRIα and IgE-Fc complex has shown that the α-chain of the 
FcεRI binds to the dimeric molecules of Cε3 domain of the IgE (Garman et al., 2000). 
In the absence of antigen, FcεRIα does not aggregate and the aggregation of the 
receptors would only take place if IgE are bound to the receptor and cross-linked by 
multivalent allergens (Turner and Kinet, 1999). The aggregation of the FcεRI 
receptors on the surface of mast cells will initiate numerous signaling pathways, 
resulting in secretion of inflammatory mediators as well as cytokines due to the 
induction of cytokine gene transcription (Turner and Kinet, 1999).  
 
The FcεRI does not compose of only the α-chain that interacts with Fcε. The 
receptor is expressed on the surface of mast cells and basophils as a multimeric αβγ2 
complex (Nadler et al., 2000). The β chain and two γ chains are responsible for 
signaling cascades by acting as phosphoreceptor for tyrosine kinases. Each of the β 
and γ chains contain one ITAM (immunoreceptor tyrosine-based activation motif) in 
their respective cytosolic portions. Signal transduction that followed the aggregation 
of FcεRIα receptors involves activation of two main tyrosine kinases, Lyn and Syk. 
ITAMs of β and γ chains will be phosphorylated by Lyn and followed by recruitment 
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and activation of Syk to the ITAMs of γ chains (Abbas and Lichtman, 2003). 
Recruitment and activation of Lyn and Syk will lead to a long series of signaling 
events which eventually result in phosphorylation of myosin light chains by activated 
protein kinase C. This is followed by the break down of actin-myosin complexes and 







Figure 1.1. Mechanisms of allergic reaction. In the first encounter of allergen, 
allergen will be taken up by dendritic cells and presented to Th2 cells triggering 
release of Th2 cytokines such as IL-4, IL-5, IL-9 and Il-13. Th2 cytokines will 
stimulate antibody class switching and production of IgE antibodies. Pro-
inflammatory mediators will be released by mast cells once mast cells-bound IgE 
antibodies are cross-linked by the allergen. Pro-inflammatory mediators such as 
histamine and leukotrienes will further cause acute allergic reactions such as 




1.2 Dust mite, an important source of allergens 
 
House dust mites belong to the phylum Arthropoda, subphylum Chelicerata, class 
Arachnida, order Acari, and suborder Astigmata. Most of the dust mites found in 
household dust and responsible for inducing allergic reaction belong to the family 
Pyroglyphidae. The most common species of house dust mites worldwide are 
Dermatophagoides farinae, Dermatophagoides pteronyssinus and Euroglyphus 
maynei (Arlian and Platts-Mills, 2001).  While these species are more common in 
temperate climates, storage mite Blomia tropicalis from the family Echymyopodidae 
are more prevalent in tropical regions.  
 
 Dust mites reproduce sexually and the life cycle consists of 5 stages: egg, larva, 
protonypmh, tritonymph and adult. Adult mites have an exoskeleton, jointed 
appendages and a blood-filled body cavity (hemocoel) (Fernandez-Cladas et al., 
1999). Mites can be easily distinguished from insects in the adult stage as mites have 
four pair of legs, instead of three. The growth in population and development from 
egg to adult are both controlled by the humidity and temperature (Hart, 1998). In 
general, dust mite requires a high relative humidity from 70% to 90% to complete 
their life cycle, with an optimum temperature of approximately 25˚C (Fernandez-
Cladas et al., 1999).  
 
 The abundance of dust mites in home is one the main reasons of why dust mite 
is the major cause of asthma attacks in the world. House dust mites feed on human 
skin scales and other organic debris, and can be found in high counts on beds, carpets, 
blankets, and clothing. It has become clear now that bodies and feces of mites are the 
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most important sources of allergens (Arlian et al., 1987). They contain mainly 
enzymes and other proteins from the mites that react potently as allergens. To date, 
more than 20 groups of proteins have been characterized from dust mites showing the 
wide diversity of different proteins that are involved in causing allergic reactions 
(Table 1.1). These mite allergens are grouped according to their function, molecular 
weight and sequence homology, and numbered according to their chronological 
characterization. Among them, group 1 and group 2 allergens from dust mites are the 
two major allergens from dust mites, each count for more than 80% in IgE binding 
prevalence among patients sensitized to dust mites.  
  
 The nomenclature of allergens as recommended by World Health Organization/ 
International Union of Immunologic Societies Subcommittee (WHO/IUIS), comprises 
of the first three letters of the genus, followed by one letter from the species and one 
numeral that describe the order of discovery of the allergen (Marsh et al., 1984; King 
et al., 1994; Chapman et al., 2007) . For example, Der p 1 and Der p 2 respectively 
describe the first and second allergen proteins isolated from dust mite 
Dermatophagoides pteronyssinus. Similarly, Bet v 1 describes the first allergen 
isolated from pollen of the tree Betula verrucosa.  
  
 Group 1 mite allergen is a group of cysteine proteases with molecular weight 
around 25,000 Dalton and has been cloned from D. farinae, D. pteronyssinus, B. 
tropicalis and Euroglyphus maynei. The IgE binding prevalence for group 1 mite 
allergens is usually more than 80% of the tested population (Table 1.1). Der p 1 
isolated from D. pteronyssinus was found to be able to cleave membrane CD23, a 
low-affinity IgE receptor on B cells required for providing negative feedback signal to 
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downregulate IgE synthesis (Schulz et al., 1995). Cleavage of CD23 by Der p 1 
enhanced the production of IgE and thus the allergic responses. Schulz et al. (1998) 
have also demonstrated that Der p 1 is capable of cleaving CD25, the α-subunit of the 
IL-2 receptor on T cell. Since IL-2 cytokine is required for the propagation of Th1 
cells, the diminished IL-2 receptor may result in skewing of the immune response 
towards Th-2 type, thus boosting the allergenicity of Der p 1 and other allergens from 
dust mites. 
 
 Group 2 allergens are proteins with molecular weight of about 14,000 Dalton 
and share all beta-sheet structure with an immunoglobulin-like fold. Group 2 
allergens also have very high IgE prevalence of more than 80% (Table 1.1). The 
function of group 2 allergens from dust mites is still unknown so far, but the protein is 
believed to be able to bind to certain types of hydrophobic ligands in its core 
(Derewenda et al., 2002). Interestingly, it shares 22% identity and 40% similarity 
with human NPC2 protein, which binds to cholesterol and its mutation has been 
implicated in Niemann-Pick disease (Frolov et al., 2003).  Group 2 allergens have 
been isolated from D. pteronyssinus, D. farinae, B. tropicalis, E. maynei, 
Glycyphagus domesticus, Acarus siro and Tyrophagus putrescentiae. Several 
polymorphisms have been identified in group 2 allergens, with more than 10 isoforms 







Group Biochemical Function 




1 Cysteine protease 25,000 80-100 
2 Unknown 14,000 80-100 
3 Trypsin, serine protease 25,000 16-97 
4 Amylase 57,000 30-74 
5 Unknown 15,000 50-70 
6 Chymotrypsin, serine protease 27,000 40 
7 Unknown 24,000 50 
8 Gluthatione-S-transferase 26,000 40 
9 Collagenolytic serine protease 26,000 90 
10 Tropomyosin 37,000 50-95 
11 Paramyosin 102,000 80 
12 Unknown 16,000 50 
13 Fatty Acid Binding Protein 15,000 10-23 
14 Vitellogenin/ apolipophorin-like 177,000 90 
15 Chitinase 62,500 70 
16 Gelsolin 55,000 35 
17 Calcium binding protein 30,000 35 
18 Chitinase 60,000 60 
19 Anti-microbial peptide 7,000 10 
20 Arginine kinase 40,000 40 
 
 
Table 1.1. Classification of dust mite allergens (adapted and modified from Thomas 
et al., 2002). The allergens are grouped based on their function and sequence 





1.3 Structural and epitope characterization of allergens 
1.3.1 Structural biology of allergens 
 
Structural studies of allergenic proteins are essential in identification of structural 
attributes that would give rise to allergenic properties of a protein. Both x-ray 
crystallography and multi-dimensional NMR have been commonly used to study 3-
dimensional structures of allergens. The list of available 3D structures of allergen is 
shown in Table 1.2. 
 
So far, more than 40 structures of allergens have been solved by using both x-
ray crystallization and NMR techniques. These allergens are from various different 
sources such as dust mites, horse, cow, rat, mouse and rubber latex. One of the early 
objectives of studying allergen structures is to identify structural motifs that could 
make an allergen to be allergenic. Different groups of allergens, however, seem to 
adopt different structural characteristics and do not suggest a single structural motif or 
fold that would solely contribute to their allergenicity. Aalberse (2000) in his review 
paper has generally classified allergens into 4 structural families based on the 
experimental 3D structures and homology models: 
1. Anti-parallel β-strands 
2. Anti-parallel β-strands associated with one or more α-helices 





Numerous structural studies on allergens and their epitope mapping suggest 
that all IgE epitopes are conformational as it involves residues from different parts of 
the linear protein sequence (Aalberse, 2000).  One of the most well studied birch 
allergen, Bet v 1 has been well characterized for its 3D structure and IgE epitope 
(Gajhede et al., 1996; Mirza et al., 2000; Spangfort et al., 2003). Structure of Bet v 1 
consists of 7 β-strands and 3 α-helices forming a globular protein with molecular 
weight of around 17,500 Dalton. One recent study has used an approach to mutate 
surface residues of Bet v 1 at several surface areas on the molecule to modulate its 
IgE binding properties (Holm et al., 2004). Two hypoallergenic mutants with 4 and 9 
surface amino acids substitutions respectively have been generated. These mutations 
covered up to 5 different areas on the surface of the molecule and changed the IgE 
binding properties of Bet v 1 significantly.  
  
Another major allergen that has been extensively studied is Der p 2, a major 
group 2 allergen from dust mite D. pteronyssinus. This 14 kDa protein is an all β-
sheets protein and the structure has been solved by both NMR and x-ray 
crystallography (Mueller et al., 1998; Derewenda et al., 2002). The structure retains 
an immunoglobulin fold, which consists of a β-barrel composed of two 3-stranded 
anti-parallel β-sheets (Mueller et al., 1998; Derewenda et al., 2002). The overall fold 
is being held by 3 disulphide bridges and these disulphide bridges have been shown to 
be important for the structural integrity of group 2 allergens. A large internal cavity 
was identified between the two β-sheets, which indicates that group 2 allergens might 
bind to hydrophobic ligands and the binding may be important to its physiological 
function in dust mites (Derewenda et al., 2002). NMR structure of Der f 2 has also 
been determined (Ichikawa et al., 1998), and it was later shown to be structurally 
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similar to human NPC2 protein, which is a cholesterol binding protein (Ichikawa et 
al., 2005). By using hydrogen exchange NMR spectroscopy and mutagenesis studies, 
the IgE binding epitopes have also been mapped to several surface residues of Der p 2 
(Mueller et al., 2001).  
 
The structure of another important allergen from dust mite, Der p 1 has been a 
mystery, until the crystal structures of both pro-Der p 1 and mature Der p 1 have been 
solved recently (Meno et al., 2005 and de Halleux et al., 2006). Both forms of Der p 1 
exhibited an α-β structure, with a typical papain-like cysteine protease fold. The pro-
peptide region was comprised of 4 α-helices, which extended and interacted with the 
active site cleft and was shown to cover several IgE binding epitopes on the mature 
protein domain (Meno et al., 2005). Three disulphide bridges were employed to 
stabilize the overall structure of mature the protein. The mature protein also contains a 
magnesium binding site and forms a dimer with extensive dimeric interface (de 






Source/ Organism Allergen name Biological function PDB code 
Anti-parallel beta strands  
Dust mite Der p 2 Unknown 1KTJ, 1A9V 
 Der f 2 Unknown 1AHK 
Grass Phl p 2 Unknown 1BMW, 1WHO 
Antiparallel β-sheets intimately associated with one or more alpha helices  
Tree/ Birch Bet v 1 IPR Proteins, Ribonucleases 1BTV, 1BV1 
 Bet v 2 Profilin, Actin binding 1CQA 
Mouse Mus m 1 Urinary Protein, Pheromone binding 1MUP 
Rat Rat n 1 Urinary Protein 2A2G 
Cow Bos d 2 Lipocalin 1BJ7 
Horse Equ c 1 Lipocalin 1EW3 
Cockroach Bla g 2 Aspartic protease 1YG9 
Dust mite Der f 13 Fatty acid binding protein 2A0A 
Alpha-beta structures, in which the α and β structural elements are not intimately associated  
Dust mite Der p 1 Cysteine protease 1XKG, 2AS8 
Chicken (egg) Gal d 4 Lysozyme 1HEL 
 Gal d 3 Ovotransferrin 1OVT 
Milk Bos d 4 Albumin, Lactalbumin 1HFZ 
Bee  Api m 1 Phospholipase 1POC 
Alpha helical structures  
Insect  Chi t 1 Hemoglobin 1ECO 
Bee Api m 3 Melittin 2MLT 
Cat  Fel d 1 Uteroglobin 1PUO 
Other structures 
Chicken (egg) Gal d 2 Ovalbumin 1OVA 
Plant (rubber) Hev b 6 Hevein 1HEV 
Fungi Asp f 1 Ribonucleases 1AQZ 
Ragweed (Pollen) Amb t 5 Unknown 1BBG, 2BBG 
 
Table 1.2. List of allergen structures The structures are grouped according to its overall 
secondary structure folding. Only experimental allergen structures solved by NMR or x-ray 
crystallization were included in this table (adapted and updated from Aalberse, 2000). 
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1.3.2 IgE epitope mapping of allergens 
 
 
There has been a keen interest in the scientific community to identify the IgE binding 
epitope of the allergens. By mapping the IgE epitope, it will help us to distinguish the 
part of the protein that is responsible for IgE binding and thus cross-linking of the Fcε 
receptor to release pro-inflammatory mediators. If the IgE epitope is known, strategic 
mutations can be attempted to alter the wild-type allergen into a hypoallergenic 
molecule that can be used as a potential vaccine for immunotherapy. Besides, 
knowledge on the locations of the epitopes, their charges and distribution will enable 
us to understand the basis of interaction between IgE and allergens. 
  
 Several strategies have been employed in attempts to study the IgE epitope of 
allergens. One of the most widely used and simplest methods is the use of site-
directed mutagenesis to identify single residues that are involved in IgE binding. This 
is usually accompanied by various IgE detection methods such as ELISA or 
immunodotblot methods to determine whether these mutations would affect its 
binding to the IgE from patients’ sera. As these single mutations usually will not 
disrupt the secondary or tertiary structure of the protein, this strategy is useful in 
identifying unique residues that are involved in IgE binding. One way to perform 
mutagenesis is to select surface residues for mutations as they are more likely to be 
involved in the surface-to-surface interaction with IgE antibody. Such structure-based 
method can be greatly useful especially if the experimental 3D structure of the 
allergen is available. Selection of candidates for mutation can also be aided by 
selecting residues that are conserved among other cross-reactive allergens or by 
analyzing sequences aligned with non-allergenic homologous proteins to determine 
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unique residues in allergens that are different from those in the non-allergenic ones. 
Such site-directed mutagenesis approaches have been successfully employed to map 
the epitopes of Hev b 6.02 (Karisola et al., 2004), Der p 2 (Mueller et al., 2001) and 
Bet v 1 (Spangfort et al., 2003).  
 
 Although X-ray crystallization provides an important tool for the study of 
structure of protein complexes, there are no available structures on the complex 
formed between IgE and allergen so far. One of the biggest hurdles is that it is highly 
difficult to obtain a large amount of homogenous IgE to complex with any of the 
allergens. IgE from patients’ sera are usually present in very low titer compared to 
other types of immunoglobulin, and normally would not exist in a homogenous 
manner. In addition to that, an allergen usually contains multiple epitope sites and 
may bind to more than one IgE antibody molecule, thus making crystallization 
process more difficult. An indirect approach, however, has been used by using 
monoclonal antibody (IgG) to complex with the allergen of interest. The monoclonal 
antibody used must be able to cross-inhibit sera IgE from binding to the allergen. This 
approach has been successfully employed by Mirza and co-workers (2000) to 
determine the structure of the complex formed between Fab fragment of a murine 
monoclonal antibody IgG, BV16 and the major pollen allergen Bet v 1. Although the 
monoclonal antibody is shown to inhibit the binding of allergic patients’ IgE to Bet v 
1, it does not necessarily binds at the IgE epitope as the inhibition of IgE binding may 
be due to steric hindrance caused by the monoclonal IgG binding to adjacent IgE 
epitope. It is, however, still the only available complex structure of an allergen and an 
antibody, while the actual complex structure of an allergen and IgE still remains 
elusive at this moment.  
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 IgE epitopes can also be mapped by measuring the amide proton exchange 
rates of the backbone amides in the allergen when it is in complex with an antibody. 
In this technique, 15N-labeled allergen was loaded onto a column with immobilized 
antibody and allowed to bind to the antibody before buffer containing 100 % D2O is 
added. At this step, free hydrogen of the amide will exchange with deuterium in the 
buffer, while residues in contact with antibody will have their amide hydrogen 
protected from exchange. Therefore, the binding epitope can be identified by locating 
remaining peaks in the 1H-15N HSQC spectrum. However, this technique still relies 
on monoclonal IgG as large amount of antibody is required. This approach has been 
successfully applied by Mueller et al. (2001) to map the IgE epitopes on Der p 2 that 
were also confirmed by mutagenesis studies. 
 
 Besides methods mentioned above, several other approaches have been 
employed to map the IgE epitope. Proline residues have been specifically targeted for 
mutations during epitope mapping of Der p 2 (Takai et al., 2000). However, proline 
mutations usually could not pin-point the exact epitope residues as prolines are 
usually essential for the structure and its mutation might lead to extensive 
conformation changes that render the protein unable to bind IgE. Peptide mapping 
strategy has also been employed to study the epitope of Jun a 1 (Midoro-Horiuti et al., 
2003) by using over-lapping peptides consisting of 13 amino acid residues. This 
approach also has its drawback as it is only valid when the IgE binding site consists of 
linear epitopes while most of the IgE epitopes are conformational epitopes (Aalberse, 
2000). Although the two methods mentioned above may not be able to define epitope 
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regions or residues with absolute certainty, they are still very useful for the creation of 
hypoallergenic molecules.  
 
 
1.4 Specific immunotherapy against allergy: Strategies to create 
hypoallergen 
 
Most of the pharmacological treatments against allergy have been targeted against 
immediate or late symptoms of allergy. Specific immunotherapy remains the only 
curative approach against allergy. It was found that immunotherapy with bee venom 
has resulted in the depletion of Th2 cytokines such as IL-4 and IL-5 but with the 
increase of Th1 cytokines secretion such as IFN-γ (Jutel et al., 1995). IL-4, IL-5 and 
IL-13 are critical in the development of Th2 cells while Th1-type cytokines such as 
IFN-γ and IL-12 play negative regulatory role in development of Th2 cells. By 
reversing the T cell responses from Th2 to Th1, production of IgE antibodies will be 
reduced while production of blocking IgG antibodies will be induced. Detailed studies 
have shown that blocking IgG antibodies induced in immunotherapy are able to block 
IgE antibodies from binding to an allergen’s epitopes, thus preventing the cross-
linking of Fcε receptors and the release of pro-inflammatory mediators (Vrtala et al., 
1998; van Neerven et al., 1999; Holm et al., 2004 and Niederberger et al., 2004).  
 
Local and systemic side-effects such as anaphylactic shocks remain the major 
concerns when increasing dosages of native allergen extracts that still retained its 
allergenicity are used for immunotherapy (Valenta, 2002). Previous immunotherapy 
attempts using birch pollen extracts have been hampered when patients were found to 
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be sensitized to develop IgE against new allergenic components (Moverare et al., 
2002). Therefore, native allergen extracts are not acceptable for such immunotherapy 
efforts, prompting demands for preparations of allergenic molecules with reduced 
allergenicity aptly name as hypoallergens. More focus now has been placed on 
creating hypoallergens preparation with its allergenicity reduced or abolished and will 
not cause any IgE-mediated side effects (Valenta, 2002). Although chemical 
modification of allergens is possible, the usage of recombinant DNA technology to 
create a hypoallergen proves to be highly useful and have shown promising results 
thus far.  
 
Recombinant DNA technology has been commonly used to modify allergens 
for allergen-specific immunotherapy. IgE binding epitopes can be removed from the 
allergen to prevent the protein from eliciting IgE-mediated response when used as a 
vaccine. However, T-cell epitopes need to be preserved in the hypoallergen to ensure 
that the vaccine still retains its immunogenicity, while inducing a non-Th2 type 
response (Akdis and Blaser, 2001). Preferably, proliferation of Th1 or regulatory T 
cells are induced instead, leading to the secretion of cytokines associated to these T-
cells (Kay, 2001). Proliferation of Th1 cells lead to subsequent production of IgG or 
IgA that are potential blocking antibodies to block the binding of IgE to allergens. 
Several strategies will be discussed in this chapter, which have been widely applied to 
remove the IgE epitope of an allergen while retaining its T-cell epitope.  
 
IgE binding epitopes can be mapped by using several methods as discussed in 
the earlier chapters. Mutagenesis approach has been employed to identify as well as to 
remove residues involved in the interaction with IgE. Holm et al. (2004) have used 
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site directed mutagenesis to create mutants of Bet v 1 with either 4 point mutations or 
9 point mutations. The structures of these mutants remain intact and the mutants 
showed reduced IgE binding, caused reduced histamine release from human basophils 
and are still capable to induce proliferation of T cells. Blocking IgG antibodies were 
also raised from mice immunized with these mutants, indicating that these mutants 
were able to induce blocking antibodies although the IgE epitope has been removed. 
Similar approach has been used to create a hypoallergen for the major latex allergen 
hevein, Hev b 6.02 by mutating its conformational IgE epitope (Karisola et al., 2004).  
 
 Structural integrity of an allergen plays an important part in eliciting IgE-
mediated response, especially when B-cell epitopes of allergens are usually 
comformational epitopes. Several attempts have been made to disrupt the 
conformation of group 2 allergens from dust mites by altering the cysteine residues of 
the allergen (Takai et al., 1997 and Olsson et al., 1998). With the conformation 
disrupted, the group 2 mutant allergens lost its IgE epitopes but retained its T-cell 
epitopes, thus making them a good candidate for hypoallergens. But on the other 
hand, this approach of altering cysteine residues seems to be only useful for allergens 
that rely on disulphide bonds for their structural integrity. Additionally, the ability of 
these unstructured mutants to raise blocking IgG antibodies may be compromised as 
IgG antibodies that are specific to both the structure and sequence of the wild type 
allergen may not be raised. 
 
 A number of efforts have been carried out to fragment the allergens in order to 
disrupt its IgE epitope while retaining the T-cell epitope. This method usually utilizes 
short peptide fragments, which represent major T-cell epitopes of the allergen. Two 
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recombinant fragments of Bet v 1 comprising amino acid 1-74 and amino acids 75-
160 have shown reduced allergenic activity, but retained their similar 
lymphoproliferative activity and are able to induce IgG antibodies that cross-reacted 
with native Bet v 1 (Vrtala et al., 2000). In separate studies targeting cat and bee 
venom allergies, immunotherapies targeting T-cell epitope using T-cell peptide have 
managed to suppress secretion of Th2 cytokines (Marcotte et al., 1998 and Muller et 
al., 1998).  
 
 Another interesting approach to create hypoallergens is to make oligomers of 
allergens by expressing several recombinant allergens together as a single molecule. 
This approach has been demonstrated in the generation of dimers and trimers of Bet v 
1 which shown greatly reduced in skin prick reactivity but are still able to stimulate 
Bet v 1-specific T-cell clones (Vrtala et al., 1999). Similar observations were also 
made on a recombinant fusion protein of two bee venom major allergens, Api m 1 and 
Api m 2 from Apis mellifera, which induce T-cell proliferation but with reduced IgE 
reactivity and histamine release (Kussebi et al., 2005). Likewise, a recombinant 
chimeric protein consisting of three bee venom allergens, Api m 1/2/3, with 
overlapping amino acids comprising the entire T-cell epitopes was generated 
(Karamloo et al., 2005). This chimeric fusion protein acts as a single molecule that 
preserves T-cell epitope repertoire from three different allergens, but with its IgE 
epitopes disrupted.  
 
 Recombinant DNA technology has enabled us to specifically target T-cells 
epitopes while abrogating the IgE epitopes in order to generate a safer and 
standardized hypoallergen preparation. The general objectives are to abolish the IgE 
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epitopes thus reducing the risk of anaphylactic side-effects, and to skew the T cells to 
produce Th1 or regulatory T cells cytokines. There is not a single or a ‘gold standard’ 
strategy so far to engineer a hypoallergen. But having said that, the variety of 
strategies available today will enable us to combine different strategies in the future to 
genetically engineer a hypoallergen that is much more effective and specific in 
immunotherapy. 
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1.5 Group 13 dust mite allergens 
1.5.1 Group 13 dust mite allergen and fatty acid binding proteins 
 
Group 13 allergen was initially discovered in cDNA library of B. tropicalis by 
Caraballo and co-workers (1997). The cDNA contains a 390 bp reading frame that 
encodes for a 130 amino acids protein, Blo t 13 with molecular weight of 14.8 kDa 
(Caraballo et al., 1997). The protein belongs to the fatty acid binding protein (FABP) 
family with significant sequence identity to human, mouse and rat FABP. Since then, 
numerous group 13 allergens have been identified from other mites such as A. siro 
(Eriksson et al., 1999), L. destructor (Eriksson et al., 2001) and T. putrescentiae 
(Jeong et al., 2005). Allergenicity prevalence of group 13 allergens have been 
characterized and ranged from 10% to 23% (Caraballo et al., 1997 and Eriksson et al., 
1999).  
   
Fatty acid binding proteins are small cytosolic proteins that assist in 
transportation of fatty acids. In humans, FABPs are highly tissue specific and have 
been characterized from at least eight different tissues (Zimmerman et al., 2001). The 
three-dimensional structures of these human FABPs have been extensively 
characterized and found to be highly conserved (Balendiran et al., 2000; Rademacher 
et al., 2002 and Gutierrez-Gonzalez et al., 2002). Although their amino acid sequence 
similarities may vary between 20 to 70%, they all adopt similar α-β structures 
comprised of a typical β-barrel of 10 anti-parallel β-strands and a pair of α-helices 
adjacent to it (Figure 1.2). FABPs would bind to fatty acids at the core of the β-barrel 
to maintain the solubility of the ligands. These FABPs showed different specificities 
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and affinities for fatty acids which may play an important role for their specific 
biological functions at certain cells and tissues (Zimmerman et al., 2001).  
 
Like other FABPs, Blo t 13 contains mainly β-sheet in its secondary structure 
as shown by using circular dichroism analysis (Puerta et al., 1999). Preliminary 
studies done by Puerta et al. (1999) using fluorescence-based ligand binding studies 
have shown that Blo t 13 binds to cis-parinaric acid and oleic acid but not to other 
fatty acids tested such as retinol, retinoic acid, cholesterol, dansylated or 
anthroxylated fatty acids (Puerta et al., 1999). Since FABPs in human have very high 
ligand specificity (Zimmerman et al., 2001), these results may imply that Blo t 13 and 
its paralogs co-exist and function to bind different ligands performing important 
functions in the physiology of mites.  
 
IgE binding prevalence studies of numerous group 13 allergens have been 
carried out and results suggested that the IgE binding frequencies to these allergens 
are fairly low. The IgE binding prevalence were found to be 11% for Blo t 13 
(Caraballo et al., 1997), 23% for Aca s 13 (Eriksson et al., 1999), 13% for Lep d 13 
(Eriksson et al., 2001) and 6.4% for Tyr p 13 (Jeong et al., 2005). Although this 
group of allergen may be categorized as a minor allergen based on its low IgE 
prevalence, inhibition studies have shown that Blo t 13 and Tyr p 13 can inhibit more 
than 60% of the IgE binding to crude mite extracts in patients with strong IgE reaction 
(Caraballo et al., 1997 and Jeong et al., 2005). Therefore, this group of allergens 
might be clinically important to certain patients that react strongly to them although 






Figure 1.2. Structures of human FABP. The structures of all human FABP are 
highly conserved with a 10-stranded β-barrel and 2 α-helices. Ribbon diagrams of 
human adipocyte, brain and heart FABPs are shown here for PDB structures adapted 




1.5.2 Der f 13, a newly characterized group 13 allergen from 
Dermatophagoides farinae 
 
A recent work on the expressed sequence tags (EST) of D. farinae and B. tropicalis 
has uncovered numerous allergenic components, in particularly two paralogs of group 
13 allergens from D. farinae and another three group 13 paralogs from B. tropicalis 
(Ong, 2003). DF414, one of the group 13 paralogs from D. farinae that shares 80% 
identity with Blo t 13, has since been aptly renamed to Der f 13 as the major form of 
group 13 allergen from D. farinae. Der f 13 also shares high levels of amino acid 
sequence homology to other group 13 allergens (Figure 1.3), with 81% and 58% 
identity to Lep d 13 and Tyr p 13 respectively.  
  
As shown in Figure 1.4, the cDNA of Der f 13 is composed of 396 bp, which 
encodes for a protein of 131 amino acids. Der f 13 has a molecular weight of 14980 
Dalton with a theoretical pI of 6.7. The protein sequence does not contain any signal 
peptide cleavage sequence or glycosylation sites as predicted in EXPASY Proteomics 
Server. It contains a very high percentage of charged residues, with 18.3% of 
positively charged residues and another 18.3% of negatively charged residues. The 
sequence of Der f 13 also aligned very well with human FABPs, with 39.1% of 
identity and 58.6% similarity to the amino acids sequences of the human brain FABP 
(Figure 3.19). 
 
The IgE binding prevalence of Der f 13 is around 48% when tested with 
immuno-dot blot using sera from 95 Singaporean and Italian patients (Ong, 2003). 
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This value is relatively higher than values of around 10-23% previously reported for 
homologous group 13 allergens from other mites. Epitope mapping of Der f 13 by 
using deletion mutations strategy has indicated that IgE antibodies reacted to group 13 
allergens are directed to the comformational epitopes (Ong, 2003). Until this study, no 
detailed structural characterization or epitope mapping studies have been carried out 








Figure 1.3. Sequence alignment of Der f 13 with other homologous group 13 
allergens. Amino acid sequence alignment was carried out using CLUSTALW 
software. Lep d 13, Blo t 13 and Tyr p 13 are group 13 allergens are from L. 
destructor, B. tropicalis and T. putrescentiae respectively. All group 13 allergens 
align fairly well with each other. Residues align with identical amino acids are 
denoted with (*) while (:) denotes aligned residues with high similarity and (.) 
denotes aligned residues with average similarity. Residues shaded in gray (Glu-41, 
Lys-63, Lys-91 and Lys-103) are aligned to epitope residues mapped on Der f 13, as 
discussed in section 3.4.1.  
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     ATG GCA AGC ATT GAA GGT AAA TAT AAA TTG GAA AAA TCG GAA AAA TTC GAT GAA TTT CTC  
1 --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 60     
  TAC CGT TCG TAA CTT CCA TTT ATA TTT AAC CTT TTT AGC CTT TTT AAG CTA CTT AAA GAG  
  Met Ala Ser Ile Glu Gly Lys Tyr Lys Leu Glu Lys Ser Glu Lys Phe Asp Glu Phe Leu  
                 
                                                                  
                                                                                  
  GAC AAA TTG GGC GTC GGT TTT ATG GTG AAA ACG GCA GCT AAA ACA TTG AAA CCA ACA TTT  
   61 --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 120    
  CTG TTT AAC CCG CAG CCA AAA TAC CAC TTT TGC CGT CGA TTT TGT AAC TTT GGT TGT AAA  
  Asp Lys Leu Gly Val Gly Phe Met Val Lys Thr Ala Ala Lys Thr Leu Lys Pro Thr Phe  
                                    
                                               
                                                                                  
  GAA GTG GCA ATT GAA AAT GAC CAA TAC ATT TTC CGT TCA TTA AGT ACG TTC AAA AAT ACT  
  121 --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 180    
  CTT CAC CGT TAA CTT TTA CTG GTT ATG TAA AAG GCA AGT AAT TCA TGC AAG TTT TTA TGA  
  Glu Val Ala Ile Glu Asn Asp Gln Tyr Ile Phe Arg Ser Leu Ser Thr Phe Lys Asn Thr  
                                                         
                          
                                                                                  
  GAA GCT AAA TTC AAA TTG GGC GAA GAA TTC GAA GAA GAT CGT GCC GAT GGT AAA CGA GTG  
  181 --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 240    
  CTT CGA TTT AAG TTT AAC CCG CTT CTT AAG CTT CTT CTA GCA CGG CTA CCA TTT GCT CAC  
  Glu Ala Lys Phe Lys Leu Gly Glu Glu Phe Glu Glu Asp Arg Ala Asp Gly Lys Arg Val  
                                                               
                    
                                                                                  
  AAA ACG GTC ATC CAA AAA GAA GGT GAC AAT AAA TTT GTT CAA ACA CAA TTC GGT GAT AAA  
  241 --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 300    
  TTT TGC CAG TAG GTT TTT CTT CCA CTG TTA TTT AAA CAA GTT TGT GTT AAG CCA CTA TTT  
  Lys Thr Val Ile Gln Lys Glu Gly Asp Asn Lys Phe Val Gln Thr Gln Phe Gly Asp Lys  
                                                                   
                
                                                                                  
  GAA GTG AAA ATT ATT CGT GAA TTC AAT GGC GAT GAA GTT GTT GTG ACT GCA TCC TGT GAT   
301 --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 360    
  CTT CAC TTT TAA TAA GCA CTT AAG TTA CCG CTA CTT CAA CAA CAC TGA CGT AGG ACA CTA  
  Glu Val Lys Ile Ile Arg Glu Phe Asn Gly Asp Glu Val Val Val Thr Ala Ser Cys Asp  
                                                                                  
                                                                     
              
  GGT GTC ACT TCC GTT CGA ACA TAT AAA CGA ATC TAA  
  361 --- --- --- --- --- --- --- --- --- --- --- --- 396    
  CCA CAG TGA AGG CAA GCT TGT ATA TTT GCT TAG ATT  




Figure 1.4. DNA sequence and translated amino acid sequence of Der f 13. 
Amino acid residues were highlighted in bold and italicized. The cDNA of Der f 13 
encoding for 131 amino acids protein has no predicted signal peptide or post-
translational modification sequences. (Adapted from Ong, 2003) 
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1.6 Blo t 5, a major allergen with coiled-coil structure from Blomia 
tropicalis  
 
Group 5 allergens from dust mites have been shown to be one of the major allergens 
isolated from dust mites, with IgE binding prevalence of between 50% and 70% 
(Thomas et al., 2002). This group of allergen has been cloned from several species of 
dust mites including B. tropicalis (Arruda et al., 1997), D. pteronyssinus (Lin et al., 
1994) and L. destructor (Eriksson et al., 2001). The cDNA of Blo t 5 encodes for a 
polypeptide chain of 134 amino acids (Figure 1.5). A signal peptide cleavage site is 
predicted to be located between residues Ala-17 and Gln-18, leaving 117 residues 
protein with an estimated molecular weight of 13,892 Dalton. So far, the function of 
this protein is not known, especially because this group of protein has very low 
sequence similarity with other known proteins in the Genbank.  
 
Based on the amino acid sequence, group 5 allergen has been identified as a 
coiled-coil protein with several heptad repeat sequences (Liaw et al., 2001). These 
heptad repeat sequences contain mainly hydrophobic residues such as valine and 
leucine at positions a and d (Liaw et al., 2001) that may form favourable hydrophobic 
packing in the coiled-coil structure (Figure 1.5). Circular dichroism studies have also 
shown that Der p 5 is an all α-helical protein that exists as a monomeric protein at 
neutral pH but forms large filament-like aggregates at low pH condition (Liaw et al., 
2001). Although crystallization and preliminary x-ray diffraction of Der p 5 has been 
reported previously (Liaw et al., 1998), structures of group 5 allergens are not 




The allergenicity and IgE binding prevalence of both Blo t 5 and Der p 5 have 
been well characterized thus far. Although both of these allergens share very high 
sequence similarity of up to 67%, the IgE binding profile of these allergens are 
actually quite distinct from each other. The Blo t 5 IgE responses are higher than Der 
p 5 when tested with sera from tropical and subtropical population (Kuo et al., 2003). 
IgE cross-reactivity between Der p 5 and Blo t 5 is relatively low although they share 
significantly high sequence similarity. This indicates that Blo t 5 may contain unique 
IgE epitopes which lead to its higher IgE binding prevalence (Chew et al., 1999 and 





    ATG AAG TTC GCC ATC GTT CTT ATT GCC TGC TTT GCC GCT TCG GTT TTG GCT CAA GAG CAC  
  1 --- --- --- +-- --- --- -+- --- --- --+ --- --- --- +-- --- --- -+- --- --- --+ 60     
    TAC TTC AAG CGG TAG CAA GAA TAA CGG ACG AAA CGG CGA AGC CAA AAC CGA GTT CTC GTG  
    Met Lys Phe Ala Ile Val Leu Ile Ala Cys Phe Ala Ala Ser Val Leu Ala Gln Glu His  
                                                                                  
                                                                                 
    AAG CCA AAG AAG GAT GAT TTC CGA AAC GAA TTC GAT CAC TTG TTG ATC GAA CAG GCA AAC  
 61 --- --- --- +-- --- --- -+- --- --- --+ --- --- --- +-- --- --- -+- --- --- --+ 120    
    TTC GGT TTC TTC CTA CTA AAG GCT TTG CTT AAG CTA GTG AAC AAC TAG CTT GTC CGT TTG  
    Lys Pro Lys Lys Asp Asp Phe Arg Asn Glu Phe Asp His Leu Leu Ile Glu Gln Ala Asn  
                                                                                  
                                                                                  
    CAT GCT ATC GAA AAG GGA GAA CAT CAA TTG CTT TAC TTG CAA CAC CAA CTC GAC GAA TTG  
121 --- --- --- +-- --- --- -+- --- --- --+ --- --- --- +-- --- --- -+- --- --- --+ 180    
    GTA CGA TAG CTT TTC CCT CTT GTA GTT AAC GAA ATG AAC GTT GTG GTT GAG CTG CTT AAC  
    His Ala Ile Glu Lys Gly Glu His Gln Leu Leu Tyr Leu Gln His Gln Leu Asp Glu Leu  
                                                                                  
                                                                                  
    AAT GAA AAC AAG AGC AAG GAA TTG CAA GAG AAA ATC ATT CGA GAA CTT GAT GTT GTT TGC  
181 --- --- --- +-- --- --- -+- --- --- --+ --- --- --- +-- --- --- -+- --- --- --+ 240    
    TTA CTT TTG TTC TCG TTC CTT AAC GTT CTC TTT TAG TAA GCT CTT GAA CTA CAA CAA ACG  
    Asn Glu Asn Lys Ser Lys Glu Leu Gln Glu Lys Ile Ile Arg Glu Leu Asp Val Val Cys  
                                                                                  
                                                                                  
    GCC ATG ATC GAA GGA GCC CAA GGA GCT TTG GAA CGT GAA TTG AAG CGA ACT GAT CTT AAC  
241 --- --- --- +-- --- --- -+- --- --- --+ --- --- --- +-- --- --- -+- --- --- --+ 300    
    CGG TAC TAG CTT CCT CGG GTT CCT CGA AAC CTT GCA CTT AAC TTC GCT TGA CTA GAA TTG  
    Ala Met Ile Glu Gly Ala Gln Gly Ala Leu Glu Arg Glu Leu Lys Arg Thr Asp Leu Asn  
                                                                                  
                                                                                  
    ATT TTG GAA CGA TTC AAC TAC GAA GAG GCT CAA ACT CTC AGC AAG ATC TTG CTT AAG GAT  
301 --- --- --- +-- --- --- -+- --- --- --+ --- --- --- +-- --- --- -+- --- --- --+ 360    
    TAA AAC CTT GCT AAG TTG ATG CTT CTC CGA GTT TGA GAG TCG TTC TAG AAC GAA TTC CTA  
    Ile Leu Glu Arg Phe Asn Tyr Glu Glu Ala Gln Thr Leu Ser Lys Ile Leu Leu Lys Asp  
                                                                                  
                                                                                  
    TTG AAG GAA ACC GAA CAA AAA GTG AAG GAT ATT CAA ACC CAA TAA  
361 --- --- --- +-- --- --- -+- --- --- --+ --- --- --- +-- --- 405    
    AAC TTC CTT TGG CTT GTT TTT CAC TTC CTA TAA GTT TGG GTT ATT  







Figure 1.5. Sequence of Blo t 5. A, Amino acid residues were highlighted in bold and 
italicized. The cDNA of Blo t 5 encodes for a 134 amino acids protein with a 
predicted signal peptide cleavage site between residues 17 and 18. B, Amino acid 
sequence of Blo t 5. Actual construct of Blo t 5 used in this study is from residue Lys-
23 onwards as underlined. Boxed residues shown are located at position a and d of the 
heptad repeat that are involved in coiled-coil formation.  
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1.7 Nuclear Magnetic Resonance 
1.7.1 Basics of NMR 
 
To date, there are only two methods to study protein or macromolecules structure at 
atomic level, which are x-ray crystallography and nuclear magnetic resonance 
(NMR). Nuclear magnetic resonance (NMR) spectroscopy remains the only tool to 
observe the protein structure in solution and its importance has lead to tremendous 
development in the methodology and improvement in both hardware and software 
tools. Although slight variances can occur in some structures determined by NMR and 
x-ray crystallography, they generally do agree with each other. As some may argue 
about the relevance of 3D structures in crystal form, NMR provides an alternative 
platform to investigate the structure in solution, which is closer to the physiological 
conditions of macromolecules. The solution state allows protein to move freely, 
enabling NMR spectroscopists to examine the dynamics and flexibility of proteins in 
relevance to their functions.  
 
 The NMR phenomenon is a result of the magnetic properties of the nucleus of 
an atom in interest. Nuclei of interest that can be studied by NMR depend on their 
nuclear spin value, I which is determined by the number of proton and neutron. 
Common biological nuclei such as 12C or 16O, which have an I value of 0 will not 
precess in a magnetic field and therefore would not give a NMR signal. However, 
other nuclei such as 1H and isotopes like 13C and 15N possess an I value of 1/2 and can 
be easily observed using NMR. When such nuclei are placed in a powerful external 
magnetic field, the spin angular momentum of the nucleus will precess and align itself 
with the external magnetic field. The alignment can be perturbed by applying an 
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electromagnetic field (or radiofrequency, RF) and the nuclei will emit NMR signal 
according to the difference in energy level between the ground and perturbed state 
(Evans, 1995).  
 
 The resonance frequency of the NMR signal emitted by the nucleus is often 
described as chemical shift, expressed in parts per million (ppm). The chemical shift 
values of different nuclei would differ depending on the different chemical 
environment of each nucleus such as the type of atom or groups it is attached to, the 
number of unpaired electrons or the type of secondary structure in which particular 
residue is located. Hence, chemical shift values would vary between atoms, even for 
the same type of atom, and would be a characteristic parameter for each atom in a 
molecule. Chemical shift values for 1H are often more useful as they are highly 
abundant in almost all biomolecules, and they can be easily detected in NMR. In 
protein NMR, protons of a particular type of amino acid would disperse in their 
chemical shifts due to factors such as hydrogen bonding, side-chain conformation, 
nature of neighbouring residues and other comformational factors due to the 
secondary and tertiary structure (Bangerter, 1995).  
 
 Structure determination using NMR techniques depends mainly on the 
distance restraints derived from NOE (Nuclear Overhauser Effect). This effect can be 
observed in NMR if there is a change in NMR signal intensity of a particular nucleus 
when the resonance of another nucleus is irradiated. NOE is a through space effect 
which depends on the distance between spatial neighbouring nuclei (Bangerter, 1995). 
This effect arises from the dipole-dipole interactions between nuclei close in space 
and therefore the extent of this effect is the greatest if the nuclei are closer to each 
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other. These effects are particular useful especially for the ‘long-range’ NOEs which 
connect atoms close in space, but far from residue sequential order.  
 
 
1.7.2 Multi-dimensional NMR and sequential assignment 
 
The effectiveness of NMR techniques to solve protein structures depends on the 
resolution of the spectra and completeness of the assigned resonances. However, this 
effort has been hampered, largely due to resonance overlap and fast relaxation of 
signals for larger proteins. This has prompted the development of multi-dimensional 
experiments with the introduction of a second or third dimension to reduce the 
overlapping problem in 1D spectra, while enabling us to measure parameters such as 
J-coupling, NOE and other types of connections between two nuclei (Wurtrich, 1986). 
By just using 2D homonuclear spectroscopy, sequence specific assignment can be 
carried out for protein up to 70 amino acids. The first procedure would involve 
correlating NMR signals which are J-coupled, which are essentially protons that are 
separated 2 or 3 bonds away. This is usually performed using COSY (Correlated 
Spectroscopy) and TOCSY (Total Correlation Spectroscopy) experiments. Once the 
spin systems have been assigned, 2D-NOESY experiment can be used to sequentially 
link the spin systems according to the protein sequence (Reid, 1997), as well as to 
provide distance restraints for structure calculation.  
 
For proteins larger than 10 kDa however, 2D NMR experiments are usually 
insufficient to provide enough resolution and information for structure determination. 
For 2D spectra for protein larger than 10 kDa, spectra will have overlapping problem 
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and many of the resonances cannot be assigned unambiguously. The longer 
correlation time of the large proteins will also give rise to shorter T2 times and a larger 
linewidth (Reid, 1997). Therefore, heteronuclear multidimensional experiments up to 
3-dimensions and 4-dimensions have been devised with increased resolution and 
sensitivity. These experiments would reduce the overlapping problems and utilize the 
through-bond correlation involving larger heteronuclear coupling. These experiments, 
however, require the protein to be isotropically enriched with 15N and/or 13C.  
 
Several series of 3D and 4D experiments have been developed to enable 
straightforward sequential assignment of the backbone and side chain resonances. 
HNCACB has been used to correlate the resonances of 1H and 15N of the backbone 
amide with the Cα and Cβ resonances of the same amino acid residue (Wittekind and 
Mueller, 1993). The resonances of the Cα and Cβ of the preceding residue may also 
be observed occasionally and will appear as a negative peak. In this spectrum, Cα and 
Cβ appeared as positive and negative peaks respectively. This experiment is usually 
paired with CBCA(CO)NH, which correlates the resonance of the 1H and 15N of the 
backbone amide with the Cα and Cβ resonances from the preceding residue (Grzesiek 
and Bax, 1993). These two experiments will allow us to connect all backbone amide 
resonances sequentially based on their side chain Cα and Cβ and provide us with the 
backbone chemical shifts assignment. Three additional 3D experiments can be carried 
out in order to complete the side-chain assignments. C(CO)NH-TOCSY will connect 
amide 1H and 15N with the all the side-chain aliphatic 13C chemical shifts of the 
preceding residue. C(CO)NH-TOCSY can also be used together with the Cα and Cβ 
chemical shifts to re-examine the type of amino acid for a spin system. H(CCO)NH-
TOCSY can link the aliphatic proton chemical shifts with the amide 1H and 15N 
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(Grzesiek et al., 1992), while HCCH-TOCSY will correlate the side chain 1H to its 
directly attached 13C (Kay, 1993).  
 
Additionally, several other experiments with increased sensitivity can be used 
to further assist sequential assignment. Highly sensitive HNCO experiment  (Ikura et 
al., 1990) that connects the amide 1H and 15N with carbonyl 13C of the preceding 
residue, is often paired with HN(CA)CO that connects the amide 1H and 15N with 
carbonyl 13C of the same residue for sequential assignment. These two experiments 
provide only chemical shifts information of the H, NH and CO, but are useful to help 
in resolving ambiguity in Cα and Cβ. Several 4D experiments have also been 
developed to further improve assignments of larger proteins and increase the protein 
size limit for NMR structural determination. Recently, Xu and co-workers (2005) 
have described new method using 4D 13C-15N-edited NOESY and MQ-(H)CCH-
TOCSY to assign resonances of aliphatic side-chain for protein up to 65 kDa. With 
further improvement in NMR methodology, the upper limit of protein size suitable for 




1.7.3 Solution structure determination using NMR techniques 
 
Upon assigning the resonances of most if not all of the spin system in the protein, the 
next crucial step is to determine the protein solution structure based on the restraints 
derived from the NMR experiments. The structure determination relies principally on 
the NOE distance restraints derived from NOESY experiments. NOEs connect 
hydrogen atoms that are close in space and separated by less than around 5 Å 
distance. These restraints are especially crucial if they are ‘long-distance’ NOEs that 
are able to connect hydrogen atoms, which are far away in amino acid sequence, but 
yet are close in space due to the folding of the protein. These long-distance NOEs will 
help to ‘fold’ the protein together and define most of the tertiary structure. In NOESY 
spectra, the volume of NOE crosspeak (V) is related to the distance between two 
interacting spins, r with V ∝ (r -6 )f (τc) , where f (τc) is a function of correlation 
time. Therefore, the stronger the NOE crosspeak, the closer the distance between the 
two protons in question. The number of NOEs used for structure calculation will 
greatly determine the resolution of the protein structure, while regions with less 
connecting NOEs are usually less defined and would have larger R.M.S.D.. 
 
 Scalar coupling constants between atoms separated by 3 covalent bonds, 
3JHNHα , can be used to define the enclosed dihedral angle, φ and are essential to 
determine the local conformation of the protein. Chemical shift values of 13Cα and 
13Cβ can also be used to assist in the structural determination by comparing the 
experimental values with their random coil values (Spera and Bax, 1991). The 
deviation of the chemical shifts from the random coil values (for each specific amino 
 40 
acids) is correlated with the backbone conformation and may be used to predict the 
secondary structure of the polypeptide. For α-helical conformation, 13Cα chemical 
shifts of each specific amino acid type tend to be larger while chemical shifts of 13Cβ 
and 1Hα tend to be smaller than random coil values. The trend seemed to be opposite 
for β-sheet conformation, with larger 13Cα and smaller 13Cβ and 1Hα values than 
random coil values.  
 
 Hydrogen exchange experiment can be used to determine the amide hydrogens 
that are involved in forming hydrogen bonds. This experiment is usually carried out 
by exchanging the protein with buffer containing 100% D2O for a few hours and then 
the 1H-15N HSQC spectrum is compared with that acquired in normal H2O buffer. 
Amide hydrogen involved in forming hydrogen bonding will be more resistant to 
deuterium exchange and would appear in the HSQC spectrum. Amide hydrogen 
exposed to the solvent and not forming hydrogen bond would disappear in the HSQC 
spectrum. Backbone dihedral angle phi (φangle) and psi (ψangle) can be predicted 
using TALOS programme (Cornilescu et al., 1999) based on the amino acid sequence 
as well as 13Cα, 13Cβ, Hα and 15N chemical shifts.  
 
All the restraints mentioned above could be effectively used for structure 
calculation to generate an ensemble of structures that best represents the restraints 
used. Two of the most widely used program DYANA (Guntert et al., 1997) and its 
extended program CYANA (Herrmann et al., 2002) calculate protein structures based 
on the distance and angle constraints by using torsion angle dynamics. Module 
CANDID in CYANA program also allows automated NOE assignment that uses 
network-anchoring and constraint-combination to generate correct polypeptide folds 
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and NOE assignments. With several rounds of calculations, the best ensemble of 
structures can be generated with the lowest target function and R.M.S.D. values. 
NMR conformers generated can be checked with the program PROCHECK-NMR 
(Laskowski et al., 1996) and the dihedral angles can be checked using Ramachandran 
plots. The final structures can be further refined by undergoing energy minimization 
using the program AMBER (Pearlman et al., 1995).  
 
 
1.7.4 Preparation of NMR Sample 
 
Most of the protein samples used for NMR experiments have been produced as 
recombinant protein from Escherichia coli. Recombinant DNA technology has 
allowed over-expression of protein in E. coli or other organisms such as yeast or 
insect cells. By subcloning the cDNA encoding the protein into plasmid with an 
inducible promoter, the expression of protein can be controlled accordingly with the 
addition of an inducer. Most of the plasmids used contain specific tags such as His-tag 
and gluthathione-S-transferase (GST) tag to help the purification and solubility of the 
protein of interest. For protein samples that required incorporation of isotope label 
such as 13C or 15N, M9 minimal medium containing 13C labeled glucose and/or 15N 
labeled ammonium chloride can be used effortlessly to grow the bacterial cells.  
 
 Protein produced as recombinant protein from E. coli required multiple 
purification steps to remove unwanted bacterial proteins that may interfere with the 
NMR experiments. Protein can be released from the cytoplasm of the bacteria by 
using many different techniques such as sonication, French-press or by using multiple 
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freeze-thaw cycles. Once the protein is released in the bacterial lysate, the protein of 
interest can be isolated by using affinity chromatography such Ni-NTA and 
gluthathione-sepharose which utilized affinity tags His-tag and GST-tag respectively. 
Protease digestion can then be carried out to remove the tag, while other 
chromatography methods such as size-exclusion or ion-exchange chromatography can 
be used to further purify the protein.  
 
 Following purification, the protein of interest will need to be exchanged into a 
buffer suitable for NMR experiments. A typical NMR sample would normally be 
prepared in an aqueous solution, with the presence of between 10-50 mM of the 
buffer such as Tris-Cl, phosphate or acetate buffer to maintain the optimum pH for the 
protein. Usually, between 5-10% of D2O (final concentration by volume) will be 
added for the field frequency lock of the magnet during the experiment. Certain 
experiments may require the protein to be in 100% D2O buffer to minimize signals 
from water. However, such buffer may not be used for experiments involving 
detection of amide proton as hydrogen from the backbone amide may exchange with 
the deuterium in solvent, rendering it undetectable. NMR is an insensitive technique, 
and therefore the experiments would require to be performed at a relatively high 
concentration of protein of about 1 mM or above (Reid, 1997). However, limited 
solubility and aggregation are the usual problems as not all protein samples are stable 
enough and may aggregate at high concentration, thus preventing acquisition of good 
NMR signals. However, the buffer can be optimized to a condition where the protein 
is most stable by altering the pH, salt concentration or by adding additives such as 
reducing agents, detergents or ligands.  
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1.8 Objectives of this study 
 
The general objectives of this study are to study the structural characteristics of Der f 
13, a group 13 allergen from Dermatophagoides farinae and to investigate its IgE 
binding epitope. This will eventually lead to the generation of a hypoallergen 
molecule which can be used as a potential vaccine candidate for specific 
immunotherapy against dust mite allergy. By understanding the structural and 
allergenicity characteristics, it will also help us to postulate the attributes of an 
allergen and what distinguish them from non-allergens. The solution structure of Blo t 
5, a major group 5 allergen from Blomia tropicalis is also of interest and will be 
investigated using NMR spectroscopy techniques. 
 
The specific aims of this study include: 
1. To solve the NMR solution structure of Der f 13 and to understand the 
structural differences with other FABP 
2. To map the IgE epitopes of Der f 13 by using site-directed mutagenesis 
in order to identify specific residues that are involved in the binding to 
IgE antibodies 
3. To generate mutants of Der f 13 with reduced IgE binding and mast 
cell cross-linking ability 
4. To test the unique mutants for its hypoallergenic characteristics such 
as: 
i. Reduced IgE binding and skin prick test reactivity 
ii. Preserved T-cell proliferation and reactivity 
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iii. Reduced Th2 cytokines but increased Th1 or Treg 
cytokines production 
iv. Ability to raised blocking IgG from mouse model 
5. To perform backbone chemical shifts assignment of Blo t 5 for further 
solution structure determination and IgE epitope mapping studies. 
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Chapter 2: Materials and Methods. 
2.1 Generation and subcloning of Der f 13 and its mutants into 
expression vector 




F- φ80dlacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17(rk-, 
mk+) phoA supE44 λ- thi-1 gyrA96 relA1 
BL21-DE3 F- ompT hsdSB(rB-mB-) gal dcm 
 
 
2.1.2 Generation of DNA insert and Polymerase Chain Reaction 
 
DNA insert of Der f 13 was generated by polymerase chain reaction, PCR, using 
upstream oligonucleotide primer containing BamH I restriction site and downstream 
oligonucleotide primer containing stop codon and Xho I restriction site. PCR reaction 
mix was prepared in 100 µl mix containing 1X Pfu buffer (20 mM Tris-Cl pH 8.8, 2 
mM MgSO4, 10 mM (NH4)2SO4, 10 mM KCl, 0.1% (v/v) Triton X-100, 0.1 mg/ml 
BSA), 10 µl of wild type Der f 13 DNA template (diluted 50 times), 0.4 µM of each 




PCR was carried out for 30 cycles by using 94˚C for denaturation, 52˚C for 
annealing and 72˚C for elongation, each for duration of 1 minute. The annealing 
temperature was adjusted accordingly to the melting temperature, Tm, of the primers 
used. The PCR product was analyzed on 1% agarose gel and purified by using Gel 
Extraction Kit (Qiagen) according to standard manufacturer’s protocol. 
 
 
2.1.3 Generation of DNA mutant insert for site directed mutagenesis 
 
Mutant constructs were generated by employing PCR-based overlap extension using 
designed oligonucleotide primers (1st Base) with mismatches (Ho et al., 1989). 
Primers were designed with mismatches base pairing being flanked on both 5’ and 3’ 
ends with about 9 to 15 bases each. The first round of PCR was used to generate new 
templates consisting of mismatched bases using two separate reactions with two 
different sets of primers. One set of primers being P1 and P3 while the other set 
utilized primers P2 and P4 (see Figure 2.1). The list of primers used is shown in 
Figure 2.2. PCR amplification was carried out in 25 µl mixture containing 1X Pfu 
buffer (20 mM Tris-Cl pH 8.8, 2 mM MgSO4, 10 mM (NH4)2SO4, 10 mM KCl, 
0.1% (v/v) Triton X-100, 0.1 mg/ml BSA), 0.5 µl of wild type Der f 13 DNA 
template (50 times diluted), 1 µM of each primers, 100 µM of each dATP, dCTP, 
dGTP and dCTP, and 1.25 U of Pfu DNA Polymerase (Fermentas). PCR was carried 
out with similar temperature cycling as described in section 2.1.2 and PCR product 
was purified with Gel Extraction Kit (Qiagen).  
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PCR products generated were used as new templates in a second round of 
PCR to produce new full-length template with the mismatches. PCR was carried out 
similarly as described above, except that the newly generated PCR products were 





Figure 2.1. Generation of site-directed mutants by PCR-based overlap extension.  
P1, P2, P3 and P4 are PCR primers, with P2 and P3 containing oligonucleotide 
sequence with mismatched base-pairing to create the intended mutations. In the first 
round of PCR, P1 and P3 are paired together while P2 and P4 are used in another set 
to create new DNA template for the second round of PCR. Only primers P1 and P4 
are used for the second round PCR (see Section 2.1.3 for description). 
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DF13_UP  5’ CG GGA TCC ATG GCA AGC ATT 3’ 
DF13_DOWN  5’ CCG CTC GAG TTA GAT TCG TTT ATA 3’ 
DF13_E5A_UP  5’ CG GGA TCC ATG GCA AGC ATT GCA GGT AAA 3’ 
DF13_K7A_UP 5’ CG GGA TCC ATG GCA AGC ATT GAA GGT GCA TAT AAA 3’  
DF13_E11A_UP 5’ AAA TAT AAA TTG GCA AAA TCG GAA AAA 3’ 
DF13_E11A_DOWN 5’ TTT TTC CGA TTT TGC CAA TTT ATA TTT 3’ 
DF13_K12A_UP 5’ TAT AAA TTG GAA GCA TCG GAA AAA TTC 3’ 
DF13_K12A_DOWN 5’ GAA TTT TTC CGA TGC TTC CAA TTT ATA 3’ 
DF13_K15A_UP 5’ GAA AAA TCG GAA GCA TTC GAT GAA 3’ 
DF13_K15A_DOWN 5’ TTC ATC GAA TGC TTC CGA TTT TTC 3’ 
DF13_D21A_UP 5’ GAA TTT CTC GCC AAA TTG GGC 3’ 
DF13_D21A_DOWN 5’ GCC CAA TTT GGC GAG AAA TTC 3’ 
DF13_K22A_UP 5’ TTT CTC GAC GCA TTG GGC GTC 3’ 
DF13_K22A_DOWN 5’ GAC GCC CAA TGC GTC GAG AAA 3’ 
DF13_K34A_UP 5’ ACG GCA GCT GCA ACA TTG AAA CCA 3’ 
DF13_K34A_DOWN 5’ TGG TTT CAA TGT TGC AGC TGC CGT 3’ 
DF13_E41A_UP 5’ CCA ACA TTT GCA GTG GCA ATT 3’ 
DF13_E41A_DOWN  5’ AAT TGC CAC TGC AAA TGT TGG 3’ 
DF13_N46A_UP 5’ GTG GCA ATT GAA GCT GAC CAA TAC 3’ 
DF13_N46A_DOWN 5’ GTA TTG GTC AGC TTC AAT TGC CAC 3’ 
DF13_K63A_UP 5’ ACT GAA GCT GCA TTC AAA TTG GGC 3’ 
DF13_K63A_DOWN 5’ GCC CAA TTT GAA TGC AGC TTC AGT 3’ 
DF13_D73A_UP 5’ TTC GAA GAA GCT CGT GCC GAT 3’ 
DF13_D73A_DOWN 5’ ATC GGC ACG AGC TTC TTC GAA 3’ 
DF13_R74A_UP 5’ GAA GAA GAT GCT GCC GAT GGT 3’ 
DF13_R74A_DOWN 5’ ACC ATC GGC AGC ATC TTC TTC 3’ 
DF13_K86A_UP 5’ GTC ATC CAA GCA GAA GGT GAC 3’ 
DF13_K86A_DOWN 5’ GTC ACC TTC TGC TTG GAT GAC 3’ 
DF13_D89A_UP 5’ AAA GAA GGT GCC AAT AAA TTT GTT 3’ 
DF13_D89A_DOWN 5’ AAC AAA TTT ATT GGC ACC TTC TTT 3’ 
DF13_K91A_UP 5’ GGT GAC AAT GCA TTT GTT CAA ACA 3’ 
DF13_K91A_DOWN 5’ TGT TTG AAC AAA TGC ATT GTC ACC 3’ 
DF13_K103A_UP 5’ AAA GAA GTG GCA ATT ATT CGT GAA 3’ 
DF13_K103A_DOWN  5’ TTC ACG AAT AAT TGC CAC TTC TTT 3’ 
DF13_E112A_UP 5’ AAT GGC GAT GCA GTT GTT GTG 3’ 
DF13_E112A_DOWN 5’ CAC AAC AAC TGC ATC GCC ATT 3’ 
 
Figure 2.2. List of primers used for PCR and mutagenesis studies. Primers 
DF13_UP and DF13_DOWN were primers P1 and P4 respectively as described in 
section 2.1.3 and Figure 2.1. Mismatches on primers used to generate site-directed 
mutations to alanine residues were highlighted in bold.  
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2.1.4 Preparation of DH5-α  competent cells 
 
Frozen glycerol stock of DH5α was streaked onto LB agar plate (without addition of 
ampicillin) and incubated overnight at 37˚C. A fresh single colony was inoculated 
into 10 ml of LB broth and incubated in a shaker overnight at 37˚C. One milliliter of 
overnight culture was transferred into 100 ml of LB broth and incubated in a shaker at 
37˚C with shaking speed of 200 rpm. Cells were grown until O.D. at 600 nm 
wavelength reached 0.4 and then transferred into 50 ml tubes and spun at 3,500 rpm 
for 10 minutes at 4˚C. Supernatant was removed and cell pellets were resuspended 
gently with 40 ml of cold glycerol buffer (0.1 M CaCl2, 15% glycerol) and then 
incubated on ice for 30 minutes. Cells were spun at 3,500 rpm for another 10 minutes 
at 4˚C and the supernatant was removed. The pellet was resuspended carefully in 4 ml 
of cold glycerol buffer and incubated on ice for 2 hours before aliquoted at 100 µl per 





DNA inserts were sub-cloned into pET-M, a modified pET-32a plasmid (Novagen) 
with S-tag and thioredoxin tag removed. The digestion of DNA insert was carried out 
by digesting 8 µl of purified PCR DNA product (about 50 ng/µl) with 10 U of BamH 
I (Promega) in total reaction volume of 20 µl. Two microliter of pET-M plasmid (50 
ng/µl) was digested in a separate tube with another 10 U of the similar restriction 
enzyme in total reaction volume of 10 µl. Concentrated 10X BamH I enzyme buffer 
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was added accordingly. Both tubes were incubated in 37˚C water bath for one hour. 
Subsequent digestion with a second restriction enzyme was carried out by addition of 
10 U of Xho I and 10X Xho I buffer (Promega) into each of the tubes and total 
reaction volume were added up for the plasmid tube and DNA insert tube to 20 µl and 
40 µl respectively. Tubes were incubated for another 2 hours at 37˚C water bath.  
 
Following the incubation, the plasmid and DNA insert digestion mixtures 
were extracted with 20 µl and 40 µl of phenol-chloroform-isoamyl alcohol solution 
(25:24:1 ratio) respectively. Mixtures were centrifuged at 13,000 rpm for 1 minute, 
and the upper layer was carefully transferred into a new eppendorf tube. DNA was 
precipitated by adding 1.3 µl and 2.6 µl of 5 M NaCl, followed by 53 µl and 106.5 µl 
of cold ethanol each into plasmid and DNA insert respectively.  
 
Both tubes were incubated on ice for 30 minutes and later centrifuged at 
13,000 rpm for 15 minutes at 4˚C. Supernatant was removed and washed with another 
500 µl of cold 70% ethanol. The tubes were centrifuged for another 5 minutes at 
13,000 rpm and 4˚C. The supernatant was removed and the DNA pellet was dried 
under vacuum with Speed-Vac. Dried DNA pellets of plasmid and DNA insert were 
resuspended and mixed in 8.5 µl of sterilized water. The DNA insert and plasmid 
were ligated by adding 1 µl of 10X T4 ligase buffer and 0.5 µl of T4 ligase enzyme 
(New England Biolabs). Ligation was carried out for 1 hour at room temperature 
before being transformed into DH5-α competent cells. 
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2.1.6 Transformation of ligation mix into DH5-α  competent cells. 
 
Ligation reaction was added into 100 µl of DH5-α competent cells and kept on ice for 
30 minutes. Heat shock transformation was carried out by incubating the cells at 42˚C 
for 90 seconds, followed by 2 minutes on ice. 900 µl of LB broth were added into the 
tubes before incubation at 37˚C in water bath for one hour. Cells were spun at 6,000 
rpm for 2 minutes and 900 µl of the supernatant were removed. Cell pellet was 
resuspended with the remaining medium and plated on LB agar plated supplemented 




2.1.7 PCR screening of transformant 
 
Proper insertion of DNA insert into target plasmid was verified by PCR screening of 
colonies grown on LB-ampicillin agar plate. Several colonies from each plate were 
selected for the screening. Half of a colony was picked using a sterile yellow tip and 
resuspended with 100 µl of sterile water in an eppendorf tube. The suspension was 
boiled for 5 minutes, and subsequently centrifuged at 13,000 rpm for a minute. One 
microliter of the supernatant can be used DNA template for PCR reaction.  
 
 A PCR reaction cocktail of volume 10 µl was prepared containing 1X Taq 
reaction buffer (50 mM KCl, 10 mM Tris-Cl pH 9.0, 1% Triton X-100), 0.75 mM 
MgCl2, 140 µM of each dATP, dCTP, dGTP and dCTP, 0.5 µM of each upstream 
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primer and downstream primer; and 1.5 U of Taq DNA Polymerase (Promega). One 
microliter of DNA template was added into the mixture and 30 PCR cycles were 
carried out with 1 minute denaturation at 94˚C, 1 minute annealing at 52˚C and I 
minute elongation at 72˚C for each cycle. The PCR products were analyzed on a 1.5% 
agarose gel for detection of DNA fragment of the appropriate size.  
 
 
2.1.8 Isolation of DNA plasmid 
 
Colonies that shown positive PCR screening results were cultured overnight in LB 
broth supplemented with 100 µg/ml ampicillin in a 37˚C shaking incubator. Cell 
pellets from 5 ml of overnight culture were recovered by centrifugation at 6,000 rpm 
for 15 minutes. DNA plasmid was extracted from pelleted cells by using QIAGEN 





2.1.9 Plasmid DNA sequencing 
 
Two microliters of plasmid DNA containing about 200 ng of DNA was added with 3 
µl of water, 1 µl of T7-promoter sequencing primer (3.2 µM), 2 µl of 5X Big Dye 
Buffer and 2 µl of Big Dye Terminator V3.1 (Applied Biosystems). Twenty five 
cycles of PCR reaction were carried out with denaturation step at 96˚C for 30 
seconds, annealing at 50˚C for 15 seconds and extension at 60˚C for 4 minutes. 
Following the sequencing cycle, DNA was precipitated with 3 µl of 3M sodium 
acetate, pH 4.6, 62.5 µl of 95 % ethanol and 24.5 µl of sterile water. Precipitation was 
carried out for 15 minutes at room temperature followed by centrifugation at 13,000 
rpm for 20 minutes at room temperature. Supernatant was removed, and the pellet was 
washed twice with 500 µl of 70% ethanol and centrifuged for another 5 minutes 
between each wash. Supernatant was carefully aspirated and sample was dried in a 
vacuum centrifuge before sequencing analysis on an automated sequencer, ABI 




2.2 Protein expression and purification of Der f 13 
2.2.1  Transformation of plasmid into BL21(DE3) competent cells 
 
Plasmid containing DNA insert of Der f 13 or mutants was transformed into E. coli 
BL21 (DE3) cells for the expression of recombinant protein. Transformation 
procedure was carried out as described in section 2.1.6. BL21 (DE3) competent cells 
were prepared as discussed in section 2.1.4. 
 
 
2.2.2 Protein expression 
 
A single colony of E. coli BL21 cells containing the desired plasmid was picked and 
cultured overnight in 50 ml of LB broth containing 100 µg/ml ampicillin. Ten 
milliliters of overnight culture were inoculated into 1 liter of fresh LB broth 
containing 100 µg/ml ampicillin. Cultures were grown at 37˚C in a shaker incubator 
with shaking speed of 200 rpm for approximately 2 and half hours until the O.D at 
600 nm reached 0.6. IPTG was added at final concentration of 0.3 mM to induce 
protein expression. The culture was further grown at 37˚C for additional 6 hours at 
200 rpm before harvesting by centrifugation at 6,000 rpm for 15 minutes at 4˚C. Cell 
pellets were kept at -20˚C until ready for purification. 
 
 Expression of 15N or 13C labeled protein were carried out with similar 
conditions as above, except that the cells were grown in M9 medium (Appendix I) 
supplemented with 15N labeled ammonium chloride and/or 13C labeled glucose. To 
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obtain 15N labeled sample, cells were grown in M9 medium in the presence of 15N 
ammonium chloride (Cambridge Isotope Laboratories) as the sole nitrogen source. 
For double labeled 15N and 13C sample, M9 medium with 15N ammonium chloride 
and 13C glucose (Cambridge Isotope Laboratories) as the sole nitrogen and carbon 
source respectively was used. For 10% 13C-labeled sample, M9 medium with 10% 13C 
glucose and 90% 12C glucose as the carbon source was used. 
 
 
2.2.3 Protein purification using Nickel-affinity chromatography 
 
Cells from 2 liters of culture were resuspended in 50 ml of Nickel binding buffer (20 
mM Tris-Cl pH 7.9, 0.5 M NaCl, 5 mM Immidazole). The suspension was divided 
into 4 tubes and sonicated for 1 minute each with 38% sonication amplitude. 
Sonication was carried out for 4 rounds, and the lysate was centrifuged for 30 minutes 
at 18,000 rpm and 4˚C. The supernatant was collected and the pellet was resuspended 
with another 50 ml of Nickel binding buffer. Sonication was repeated as described 
previously and the supernatant was pooled. Ni-NTA beads (Qiagen) were charged 
with Nickel-charge buffer (50 mM NiSO4), washed with water and equilibrated with 
Nickel binding buffer in a chromatography column. All supernatant was slowly 
loaded into the column with aid of peristaltic pump. The column was subsequently 
washed 10 times with a total of 300 ml of Nickel binding buffer to remove unbound 
proteins. His-tagged protein was eluted with 20 ml of Nickel elution buffer (20 mM 
Tris-Cl pH 7.9, 0.5 M NaCl and 500 mM Immidazole). The eluted protein was 
dialyzed against 50 mM Tris-Cl pH 7.9 and subjected to further analysis by SDS-
PAGE.  
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2.2.4 Protein purification using glutathione-sepharose affinity 
chromatography 
 
Cells from 2 liters of culture were resuspended in 50 ml of PBS (140 mM NaCl, 2.7 
mM KCl, 10 mM Na2HPO4 and 1.8 mM KH2PO4). The suspension was divided into 4 
tubes and sonicated for 1 minute each with 38% sonication amplitude. Sonication was 
carried out for 4 rounds, and the sonication lysate was centrifuged for 30 minutes at 
18,000 rpm and 4˚C. The supernatant was collected and the pellet was resuspended 
with another 50 ml of PBS. Sonication was repeated as described previously and the 
supernatant was pooled. All supernatant was slowly loaded into a column packed with 
10 ml of glutathione-sepharose 4B beads (Amersham Biosciences) equilibrated with 
PBS. The column was subsequently washed 10 times with a total of 300 ml of PBS to 
remove unbound proteins. GST-tagged protein was eluted with 20 ml of glutathione-
elution buffer (50 mM Tris-Cl pH 7.9 and 10 mM reduced gluthathione) and 
subjected to analysis by SDS-PAGE. Glutathione-sepharose beads were regenerated 
by washing the column twice with column regeneration buffer 1 & 2 (Appendix II).  
 
2.2.5 Thrombin digestion 
 
His-tag on recombinant protein was removed by cleaving the thrombin cleavage site 
between His-tag and the N-terminus of the protein. Digestion was carried out in 50 
mM Tris-Cl pH 7.9 and 3 mM CaCl2. Thrombin was added at 5 U/mg of protein and 
cleavage was carried out overnight at room temperature. Digestion was stopped by 
adding EDTA at pH 8.0 to a final concentration of 5 mM.  
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2.2.6 Gel filtration FPLC 
 
Gel filtration FPLC (Fast Protein Liquid Chromatography) was carried out in a 
HiLoad 16/60 Superdex 75 pg (Amersham Biosciences) size exclusion 
chromatography column on AKTA FPLC System (Amersham Biosciences) using 
Tris-Cl buffer (50 mM Tris-Cl pH 7.9 and 500 mM NaCl) as running buffer. Gel 
filtration column was pre-equilibrated with at least two column volumes of running 
buffer before use. Protein sample was concentrated to about 2 ml prior to loading into 
the column. Chromatography was carried out with a flow rate of 1 ml/min and a total 
volume of 180 ml. Eluted protein peaks were detected by absorbance at 280 nm and 
the fractions were analyzed with SDS-PAGE.  
 
 
2.2.7 Preparation of NMR sample 
 
Purified protein was concentrated to about 1 mM using an ultra-filtration concentrator 
(Centriprep YM-3, Millipore) and was exchanged into buffer containing 50 mM 
acetate buffer pH 4.5 with 10% deuterium oxide (Cambridge Isotope Laboratories). 
Concentrated protein was centrifuged at 13,000 rpm and 4˚C for at least 15 minutes 




2.2.8 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
 
SDS-PAGE was carried out according to the method described by Laemmli (1970). 
Briefly, 15% SDS-PAGE gel was casted according to the table described in Appendix 
III using the Mini-PROTEAN 3 system (Bio-Rad). Protein sample was mixed with an 
equal volume of 2X SDS sample buffer and boiled for 5 minutes. Ten microliters of 
sample was loaded into each well, and electrophoresis was carried out at 200 V until 
the marker dye reached the end of the gel. The gel was stained with Coomassie blue 
staining solution for about 20 minutes and then destained in destaining solution 
(Appendix III) for overnight.  
 
 
2.2.9 Circular dichroism spectropolarimetry 
 
Circular dichroism (CD) experiments were carried out with 10 µM protein in 50 mM 
acetate buffer pH 4.5 at room temperature. The spectra were acquired with a J-810 
Spectropolarimeter (Jasco, Japan) using a quartz cuvette with 1 mm pathlength 
(Hellma, Germany). The spectra were recorded at wavelength region from 190 nm to 
260 nm with 0.1 nm resolutions using a scan speed of 50 nm/min and a response time 




2.2.10 Sequence alignment 
 
Amino acid sequence alignment was carried out by using ClustalW (Higgins et al., 
1994) service hosted at European Bioinformatics Institute server (EBI, 
http://www.ebi.ac.uk/Tools/). Amino acid sequences of all human FABP were 
acquired from GenBank (http://www.ncbi.nlm.nih.gov/) while the sequences of 
homologous dust mite group 13 allergens were acquired from Allergome database 
(www.allergome.com). Aligned amino acid residues were compared based on their 
distinctly different properties. For example, a charged residue versus a hydrophobic 
residue, or a polar residue versus a hydrophobic residue. The sequence of Der f 13 
was first aligned with those of all human FABPs to identify residues that are 
significantly different in Der f 13 compared to the corresponding residues in human 
FABPs. Der f 13 was also aligned with other group 13 allergens from B. tropicalis, L. 
destructor and T. putrescentiae. 
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2.3 Nuclear magnetic resonance and structural determination 
2.3.1 NMR chemical shift assignments of Der f 13 
 
Several 3D heteronuclear NMR experiments were carried out to assign the backbone 
and side-chain chemical shifts using a 2D 1H-15N HSQC as a reference spectrum. All 
NMR experiments were carried out on a Bruker AVANCE 500 MHz spectrometer 
equipped with a cryoprobe. Samples were contained in a 5 mm Shigemi NMR tube 
and all experiments were carried out at 298 K. All data acquired were processed using 
NMRPipe (Delaglio et al., 1995) and viewed and analyzed using NMRDraw 
(Delaglio et al., 1995) and NMRView (Johnson and Blevins, 1994). Computational 




2.3.1.1 2D 1H-15N HSQC spectrum 
 
Two-dimensional 1H-15N HSQC spectrum was used as a basis for assigning backbone 
chemical shifts by other 3D triple resonance experiments. The spectrum was acquired 
with 1024 complex points over a spectral width of 8012.8 Hz on the amide proton 
dimension. In the 15N dimension, 256 points were collected over 1774.3 Hz. Carrier 




2.3.1.2 HNCACB and CBCA(CO)NH 
 
Backbone assignments were carried out by using HNCACB and CBCA(CO)NH 
experiments. The CBCA(CO)NH experiment correlates both the Cα and Cβ chemical 
shift with the amide from the previous residue while HNCACB provides the 
intraresidue correlation of its own Cα and Cβ. These two experiments provide 
sufficient chemical shift information to complete the sequential assignments of all 
15N, HN, Cα and Cβ resonances. 
 
 In HNCACB (Wittekind and Mueller, 1993), resonances of 1H and 15N of each 
amide group will be correlated with Cα and Cβ of the same residue, while the Cα and 
Cβ from the preceding residue will also be observed in the same amide strip but 
usually weaker. In the acquired F1 dimension (1H) of the experiment, 1024 points 
were collected over 8012.8 Hz spectral width. In the F2 dimension (15N), 68 points 
were collected over 1368.7 Hz of spectral width while the F3 dimension (13C) 
contained 104 points covering 7700 Hz spectral width or 61 ppm. The carrier 
frequencies for F1, F2 and F3 dimensions were at 4.725 ppm, 119.5 ppm and 43.0 
ppm respectively. Three dimensional CBCA(CO)NH experiment (Grzesiek and Bax, 
1993) was carried out similarly using the same data points and spectral widths as 




2.3.1.3 C(CO)NH-TOCSY and H(CO)NH-TOCSY 
 
Chemical shifts of all aliphatic 13C were collected from C(CO)NH experiment 
(Grzesiek et al., 1992) that connects resonance of amide 1H and 15N with 13C from 
preceding residue’s side chain. A total of 1024 complex points were recorded over a 
spectral width of 8012.8 Hz in the proton dimension (F1). In the amide 15N dimension 
(F2), 40 data points were recorded with spectral width of 1368.7 Hz while 104 data 
points covering 7700 Hz were recorded for the 13C dimension (F3). The carrier 
frequencies for F1, F2 and F3 dimensions were at 4.725 ppm, 118.83 ppm and 40.38 
ppm respectively.  
 
 For H(CO)NH experiment (Montelione et al., 1992), a total of 1024 complex 
points were recorded over a spectral width of 8012.8 Hz in the F1 proton dimension. 
In the amide 15N dimension (F2), 40 data points were recorded with a spectral width 
of 1368.7 Hz while 90 data points covering 3000 Hz were recorded for the proton 
dimension (F3). Carrier frequencies for F1, F2 and F3 were at 4.725 ppm, 118.83 ppm 





Three dimensional HCCH-TOCSY experiment was utilized to identify side chain spin 
system by connecting aliphatic 1H resonances with their attached 13C resonances. The 
protein sample used in this experiment was prepared by exchanging 13C-labeled 
protein with deuterated acetate buffer at pD 4.5 in 99.9% D2O. A total of 1024 
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complex points were collected for F1 dimension (1H) over 8012.8 Hz spectral width, 
while F2 dimension (indirectly detected 1H dimension) consists of 90 points over 
3000 Hz spectral width. F3 dimension (13C) was recorded with 104 data points over 
7700 Hz of spectral width. The carrier frequencies for F1, F2 and F3 were at 4.725 
ppm, 3.147 ppm and 40.135 ppm respectively.  
 
 
2.3.1.5 1H-13C HSQC 
 
Two-dimensional 1H-13C HSQC spectrum was used to carry out stereospecific 
assignment of the methyl groups. Different splitting patterns were observed in proton 
decoupled 1H-13C HSQC experiment using a 10% 13C labeled sample. Spectrum was 
acquired with 2048 complex points over spectral width of 8012.8 Hz on the proton 
dimension. In the 13C dimension, 1024 points were collected over 7000 Hz of spectral 





2.3.2 NOE distance restraints and hydrogen bond restraints of 
Der f 13 
2.3.2.1 Hydrogen-deuterium exchange measurement 
 
Hydrogen bond restraints were determined by recording 1H-15N HSQC of uniformly 
labeled 15N protein exchanged into 100% deuterium oxide buffer for 4 hours. The 
HSQC spectrum was acquired similarly as described in section 2.3.1.1. Peaks that 
appeared on the spectrum are those amide protons involved in the hydrogen-bonding 
with carbonyl groups and thus used as hydrogen bond restraints.  
 
 
2.3.2.2 15N-edited NOESY 
 
Amide proton distance constraints were derived from 3D 15N-edited Nuclear 
Overhauser Effect spectroscopy (NOESY) with 100 ms mixing time. Each cross peak 
in a 15N-NOESY amide strip represents a NOE between an amide proton to a nearby 
proton within around 5 Å distance. 1024 complex points were recorded for the F1 
dimension corresponding to the directly detected 1H dimension over spectral width of 
8012.8 Hz. For F2 dimension detecting the 15N, 60 complex points were detected over 
spectral width of 1650 Hz, while 256 complex points were recorded for spectral width 
of 5500 Hz for F3 dimension (1H). Carrier frequencies for F1, F2 and F3 were at 




2.3.2.3 13C-edited NOESY 
 
13C-edited NOESY was recorded using 13C labeled protein in buffer containing 99.9% 
D2O with a mixing time of 100 ms. In 13C-NOESY, each cross peak represents the 
NOE between a nearby proton to the particular proton attached to backbone and side-
chain 13C. A total of 1024 complex points were recorded for the F1 dimension 
corresponding to the directly detected 1H dimension over spectral width of 8012.8 Hz. 
F2 dimension detecting the 13C was recorded with 128 complex points over spectral 
width of 7000 Hz, while 256 complex points were recorded for spectral width of 4500 
Hz for F3 dimension (1H). Carrier frequencies for F1, F2 and F3 were at 4.010 ppm, 
47.56 ppm and 4.010 ppm respectively. 
 
 
2.3.3 NOE assignments and structure calculation 
 
Some of the NOEs were unambiguously assigned based on the secondary structure 
information derived from Chemical Shift Index obtained using the Cα and Cβ 
chemical shifts deviation from the random coil values. NOEs from 15N-edited 
NOESY were particularly useful to identify NOEs between NH-NH and between NH-
Hα. For α-helical type secondary structure, strong NOEs can be observed between 
NH(i+4)-Hα(i), and NH(i+3)-Hα(i) and these NOEs are not normally observed in β-
strands.  For β-strands, strong NOEs are often observed between Hα(i)-NH(i+1) as well 
as between amide protons from opposite β-strands that formed β-sheets. These 
signature NOEs can be used to unambiguously assign most of the NOEs connecting 
backbone protons.  
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 Unambiguously assigned NOEs were used to generate initial random 
structures in CYANA to enable the software to assign the remaining 15N-edited and 
13C-edited NOE restraints. Other parameters included as input data during structural 
calculation include the hydrogen bond distance restraints and dihedral angles 
predicted using the TALOS programme. Fifteen thousands steps of calculation were 
performed using standard torsion angle dynamics protocol with 100 starting 
conformers. Ten final best structures with the lowest target functions and constraints 





2.4.1 Specific IgE binding ELISA experiment 
 
For ELISA experiments, all proteins used were GST-tag fusion proteins for maximum 
binding on ELISA plate. The volumes of all reagents and sera used in ELISA 
experiments were at 100 µl per well. Sera from patients were diluted 1:3 with 1% 
BSA in PBS and pre-absorbed with 0.5 mg/ml of GST protein overnight at 4˚C. Wild 
type Der f 13 or mutants were coated overnight at 4˚C onto Maxisorp ELISA plate 
(NUNC) at 1 µg protein per well. Plates were washed with PBS-T (PBS, 0.05% 
Tween 20) and blocked with PBS-1% BSA for half an hour at room temperature. The 
plates were washed with PBS-T and incubated with pre-absorbed sera for 2.5 hours at 
room temperature.  Following washing 3 times with PBS-T, biotin conjugated anti-
human IgE monoclonal antibody (BD-Pharmingen) diluted 1:250 in PBS-1% BSA 
was added and incubated for another 2 hours.  After washing with PBS-T, avidin 
conjugated HRP (BD-Pharmingen) diluted 1:1000 in PBS-1% BSA was added and 
incubated for half an hour. The plates were then thoroughly washed with PBS-T and 
then 100 µl of TMB substrate (Sigma Aldrich) was added. The color reaction was 
detected through absorbance measurements at 655 nm using an ELISA plate reader. 





2.4.2 Inhibition ELISA experiment 
 
In a 100 µl reaction volume, 1 µg of GST-Der f 13 protein was coated onto Maxisorp 
ELISA plate (NUNC) overnight at 4˚C. Sera were pre-absorbed with 0.5 mg/ml of 
GST protein and various amounts (0.01, 0.1, 1, 10 and 50 µg) of Der f 13 or 
E41A_K63A_K91A triple mutant of Der f 13 (3A mutant). After overnight 
incubation, plates were washed with PBS-T and blocked with PBS-1% BSA for 30 
minutes at room temperature. The plates were washed again with PBS-T and 
incubated with sera pre-absorbed with Der f 13 or 3A mutant for 2.5 hours at room 
temperature. Subsequent antibodies incubation and colorimetric development were 
performed as described above in section 2.4.1. 
 
 
2.4.3 Skin prick test 
 
Written consents were obtained from allergic patients prior to the skin prick tests.  
The tests were conducted with 20 µg/ml of recombinant protein in PBS buffer 
containing 50% glycerol. All proteins and buffer used in these experiments were 
filter-sterilized with 0.22 µm filter membrane. Skin prick was carried out with sterile 
lancet and measurement of wheal and erythema was carried out after 20 minutes 
interval.  Histamine (10 mg/ml) was included as positive control while PBS buffer 
was included as negative control.  Only skin prick reactions with wheal diameter of 3 
mm or more were considered as positive results. 
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2.4.4 Isolation of mononuclear cells using Ficoll-Hypaque gradient 
centrifugation 
 
Blood samples from two patients (D2 and H3) allergic to Der f 13 were used for 
PBMC isolation. All steps involved in the PBMC isolation were performed in a fully 
sterile environment inside laminar flow hood. Five milliliters of blood freshly 
collected in heparin or EDTA tube was centrifuged at 1800 rpm for 10 minutes to 
remove plasma supernatant. Pellet was resuspended gently with 5 ml of non-
supplemented RPMI medium. The suspension was layered carefully over another 5 
ml of Ficoll-Hypaque solution (Sigma-Aldrich) in a 15 ml Falcon tube. Mixture was 
centrifuged for 15 minutes at 2000 rpm and room temperature, with the centrifuge 
brake turned off. The upper layer of supernatant was removed slowly using a transfer 
pipette. Buffy coat containing mononuclear cells was carefully transferred into a new 
tube using transfer pipette, while avoiding drawing large amount of plasma and red 
blood cells.  
 
Cells were washed with 10 ml of RPMI and centrifuged at 2,000 rpm for 10 
minutes at room temperature. Supernatant was removed slowly using a transfer 
pipette and the pellet was gently resuspended with 1 ml of RPMI solution. Diluted 
cells stained with Trypan blue dye were loaded into a hemacytometer and viewed 




2.4.5 PBMC proliferation and cytokine expression 
 
PBMC were cultured in RPMI/10% FBS medium (supplemented with 2 mM L-
glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin) in 96-wells round 
bottom plate at 1 X 105 cells per well. Wild type Der f 13 or 3A mutant were added 
into cells at a final concentration of 100 µg/ml. Equal volume of culture media was 
added into non-stimulated cells as control. PBMC were incubated for 6 days in an 
incubator at 37˚C and 5% CO2. Cells were tested for proliferation by using the WST-1 
colorimetric method according to standard manufacturer’s protocol (Biovision). 
Absorbance was measured at 450 nm and 650 nm was used as reference wavelength. 
Proliferation was reported as stimulation index with the formula (S-C)/C*100 where S 




2.4.6 Cytokines measurement 
 
PBMC were cultured similarly as described above.  At day 6, supernatant of the cell 
culture were harvested by centrifugation at 6,000 rpm for 15 minutes for the 
measurement of cytokines being produced.  Cytokine concentrations were measured 
by using human Th1/Th2 Bioplex Cytokine Assay (Bio-Rad) according to standard 




2.4.7 Mouse immunization  
 
Mouse immunization experiments were carried out to compare the abilities of wild 
type and 3A mutant of Der f 13 to induce IgG antibodies specific for Der f 13.  Eight 
weeks old female BALB/c mice were used in our studies. Groups of 5 mice were each 
injected via intraperitoneal with 15 µg of purified Der f 13 or 3A mutant (each in 
PBS) conjugated with 1.25 mg/ml aluminium hydroxide gel (Sigma-Aldrich) for 
every 2 weeks for a total of 6 immunizations. PBS buffer containing adjuvant 
aluminium hydroxide was similarly injected into another mouse as buffer control. All 
reagents used for mouse immunization were filter-sterilized before usage. Post-
immunization blood was drawn from mice 24 hours after each injection via orbital 
bleeding. Blood samples were kept at 4˚C overnight to allow blood to coagulate, and 
later centrifuged at 6,000 rpm at 4˚C to collect the sera in the supernatant. Sera were 
kept at -20˚C until analysis. Animals were maintained in the Animal Holding Unit of 




2.4.8  Mouse orbital bleeding and sera collection 
 
Orbital bleeding was carried out while the animal was under anaesthesia with 
ketamine (75 mg/kg) and medetomidine (1 mg/kg) mixture injected via intra-
peritoneal for each mouse. Reflexes of each mouse were tested to ensure animal was 
deeply anaesthetized but maintained adequate respiration. Forefinger was used to pull 
the facial skin to protrude the eyes. Hematocrit capillary tube was inserted below the 
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eye into the space between globe and lower eyelid. Hematocrit tube was gently 
twisted and blood was allowed to flow through the tube. About 300 µl of blood was 
collected from each mouse each time in a clean microcentrifuge tube. Local pressure 
was applied on the bleeding site to stop haemorrhage. Equal volume of reversing 
anaesthesia, antisedan (atipamezole hydrochloride) was injected via intra-peritoneal 
and recovery of the animal was observed. Blood collected was kept at 4˚C overnight 
and later centrifuged at 6,000 rpm for 30 minutes at 4˚C. Sera in supernatant were 
kept in -20˚C until further analysis.   
 
 
2.4.9 Inhibition of human IgE binding to Der f 13 by specific 
mouse IgG antibodies 
 
GST-tagged Der f 13 was coated overnight at 4˚C onto Maxisorp ELISA plate 
(NUNC) at 1 µg protein per well.  Plates were washed with PBS-T and blocked with 
PBS-1% BSA for 30 minutes at room temperature. Plates were washed again with 
PBS-T and incubated with 1:10 diluted mouse serum from control mouse or from 
mice immunized with either Der f 13 or 3A mutant. Plates were incubated for 2.5 
hours at room temperature. After incubation, plates were washed with PBS-T and 
incubated with 1:5 diluted pooled sera (from patients D2 and H3) in PBS-1% BSA for 
2.5 hours at room temperature. After washing with PBS-T, biotin conjugated anti-
human IgE monoclonal antibody (BD-Pharmingen) diluted 1:250 in PBS-1% BSA 
was added and incubated for 2 hours at room temperature. Following washing with 
PBS-T, avidin conjugated HRP (BD-Pharmingen) diluted 1:1000 in PBS-1% BSA 
was added and incubated for another 30 minutes. The plates were then thoroughly 
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washed with PBS-T and 100 µl of TMB substrate (Sigma-Aldrich) was added. The 
color reactions were detected through absorbance measurements at 655 nm. All 
experiments were carried out in duplicates and results were reported as mean values. 
Percentage of inhibition of human IgE binding to Der f 13 after pre-incubation with 
mouse sera were determined with the following formula: % inhibition of IgE binding 
= 100 – (ODI/ODC) × 100. ODI and ODC represent absorbance values after 
preincubation with serum from immunized mouse and control mouse respectively. 
 
 
2.4.10 Specific mouse IgG binding to Der f 13 ELISA experiment 
 
Binding of mouse IgG to wild type Der f 13 was evaluated by ELISA experiments. 
GST-tagged Der f 13 was coated overnight at 4˚C onto Maxisorp ELISA plate 
(NUNC) at 1 µg protein per well. GST protein was included at similar concentration 
in a separate well as control. Plates were washed with PBS-T (PBS, 0.05% Tween 20) 
and blocked with PBS-1% BSA for 30 minutes at room temperature. The plates were 
washed again with PBS-T and incubated with mouse sera (diluted 1:100 with PBS-
1% BSA) for 2.5 hours at room temperature. Following washing with PBS-T, goat 
anti-mouse IgG antibodies conjugated with alkaline phosphatase (Chemicon) diluted 
1:1000 in PBS-1% BSA was added and incubated for another 2.5 hours. The plates 
were then thoroughly washed with PBS-T and 100 µl of PNPP substrate (Sigma 
Aldrich) was added. The color reaction was observed through absorbance 
measurements at 405 nm using an ELISA plate reader. All experiments were carried 
out in duplicates and results were reported as mean values.  
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2.4.11  Specific mouse IgE binding to Der f 13 ELISA experiment 
 
Mouse IgE titer was measured similarly as described above for the measurement of 
mouse IgG titer (section 2.4.10) except that the mouse sera dilutions were at 1:10 and 
anti-mouse IgE antibodies were used for detection. 
 
 
2.4.12 Specific mouse IgG binding to human FABP ELISA 
experiment 
 
To determine whether IgG induced from mouse immunization would bind to human 
FABPs, similar ELISA experiments were carried out as described previously for 
specific mouse IgG binding to Der f 13 (Section 2.4.10), except that GST-tagged 
human FABPs were coated onto ELISA plate. Three human FABPs, adipocyte FABP, 
brain FABP and heart FABP were used. Pooled mouse sera were used to detect the 




2.5 Sub-cloning, expression and purification of Blo t 5 
 
A new Blo t 5 polypeptide was re-constructed by removing cDNA encoding the first 
22 amino acids residues at the N-terminal region of the protein (Figure 1.5). The 
removed fragment of 22 amino acids contains a 17-residues signal peptide region as 
well as another 5 residues region that was predicted to be unstructured due to the 
residue Pro-22. New oligonucleotide primers were designed with BamH I and Xho I 
as upstream and downstream restriction site respectively. The cDNA encoding Blo t 5 
was sub-cloned into pET-M vector as described in Section 2.1.5. Plasmid containing 
newly constructed Blo t 5 cDNA was transformed into BL21 cells for protein 
expression. Expression and purification techniques employed for Blo t 5 was similar 
to those detailed for Der f 13 in Section 2.2, except that Blo t 5 was digested for only 
1 hour with 0.5 U thrombin/mg protein. Purified Blo t 5 protein was dialyzed against 
50 mM phosphate pH 7 and kept at -80 ˚C until further analysis.  Circular dichroism 
experiment was also performed to investigate the secondary structure of Blo t 5 as 
described in Section 2.2.9. 
 
 
2.6 NMR experiments and chemical shifts assignment of Blo t 5  
 
All NMR experiments for Blo t 5 was carried out using a 2 mM protein sample in 50 
mM phosphate pH 7.0 with 10% D2O. NMR data for Blo t 5 was recorded on an 800 
MHz Bruker spectrometer at temperature of 298 K. One dimensional 1H-NMR and 
two dimensional 1H-15N HSQC were recorded to check the proper folding and peaks 
dispersion as discussed in Section 2.3.1.1. Backbone chemical shifts of Blo t 5 was 
 76 
assigned using HNCACB and CBCA(CO)NH as described in Section 2.3.1.2. NMR 
data was processed using NMRPipe (Delaglio et al., 1995) and analyzed using 
NMRView (Johnson and Blevins, 1994) and NMRDraw (Delaglio et al., 1995).   
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Chapter 3: Results and discussion 
3.1 Protein expression and purification 
3.1.1 Expression and purification of His-tag Der f 13 
 
Der f 13 was over-expressed as a soluble His-tag protein in E. coli BL21 (DE3) cells. 
The cells were sonicated and the lysates were loaded into a Ni-NTA column. Affinity 
chromatography was carried out to separate His-tagged Der f 13 from other bacterial 
proteins. The eluted protein is relatively pure after this step. Thrombin digestion was 
then carried out overnight to remove the N-terminal His-tag leaving the Der f 13 
recombinant protein and two extra residues, glycine and serine, from the vector at the 
N-terminus of the protein. The protein was further purified to high purity using gel 
filtration FPLC and the monomeric protein was eluted out at an elution volume of 77 
ml as a single major peak (Figure 3.3A). The protein appeared as a pure single band 
with an approximate size of 15 kDa when analyzed on a 15% SDS-PAGE gel stained 
with Coomassie blue (Figure 3.1). Typically, each liter of LB culture yielded about 30 
mg of soluble Der f 13 protein. The purified Der f 13 protein was dialyzed into either 
50 mM acetate buffer pH 4.5 or PBS for further characterization. For long term 




3.1.2 Protein expression and purification of GST-tag Der f 13 
 
Based on our observation that Der f 13 did not bind well onto nitrocellulose 
membrane and ELISA plate, we had chosen to express Der f 13 as a GST-tag protein 
to enhance the binding Der f 13 on ELISA plate. GST-Der f 13 expressed well as a 
soluble protein in E. coli and could be purified to a high purity using glutathione-
sepharose column. When analyzed on SDS-PAGE gel, the protein appeared with an 
approximate molecular weight of 41 kDa (Figure 3.2). A similar method was 
employed to express and purify mutant Der f 13 and human FABPs to be used for 
ELISA experiments.  
 
 
3.1.3 Circular dichroism of Der f 13 
 
Circular dichroism (CD) experiment was carried out to study the secondary structure 
of Der f 13. Overall, CD showed that Der f 13 consists mainly of β-sheet in its 
secondary structure with the spectrum showing a minimum at around 218 nm and a 
maximum peak at around 198 nm (Figure 3.3B). This observation is consistent with 






Figure 3.1. Expression and purification of His-tag Der f 13. Der f 13 was 
expressed as soluble protein in E. coli BL21. Lane 1, low molecular weight marker; 
lane 2, whole cell before IPTG induction; lane 3, whole cell after IPTG induction; 
lane 4, flow-through from Ni-column; lane 5, eluted protein from Ni-column; lane 6, 
Der f 13 after thrombin digestion and lane 7, Der f 13 after gel filtration FPLC 
 
 
Figure 3.2. Expression and purification of GST-tag Der f 13. Lane 1, low 
molecular weight marker; lane 2, whole cell before induction; lane 3, whole cell after 





Figure 3.3. Gel filtration profile and CD spectrum of Der f 13. A, Gel filtration 
profile of Der f 13 on Superdex 75 pg column. The peak corresponding to Der f 13 is 
indicated by an arrow. B, CD spectrum of Der f 13 showing a typical β-sheet 
secondary structure with a minimum peak at around 218 nm.  
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3.2 NMR Structure of Der f 13 
3.2.1 1D 1H-NMR and 2D 1H-15N HSQC spectra of Der f 13 
 
Initial 1D 1H-NMR spectrum showed that the Der f 13 is a well-folded protein with 
good amide peak dispersion between 6 ppm to 10 ppm (Figure 3.4). Signals of Hα 
were also detected at region between 5 and 6 ppm, indicate that Der f 13 consists of 
β-sheets. Several sharp peaks were also recorded at the methyl region with negative 
values. Two dimensional 1H-15N HSQC spectrum in Figure 3.5 also showed good 
dispersion of amide peaks with most of them having similar intensities. The number 
of peaks was correct except for a few extra faint peaks, which could due to 
exchanging property of the protein. Peaks correspond to the extra glycine and serine 
residues from the vector were not detected, probably due to fast exchange of the N-
terminus of the protein with solvent. Overall, the overlapping of peaks was minimal in 
the 1H-15N HSQC, and the small number of overlapped peaks can be resolved during 
assignment of the backbone chemical shifts.  
 
 
3.2.2 Chemical shifts assignment of Der f 13 
 
Backbone chemical shifts were assigned using two fundamental experiments, 
HNCACB and CBCA(CO)NH. HNCACB was used to correlate all the amide peaks 
with Cα and Cβ resonances of the same residue (Figure 3.6A) while CBCA(CO)NH 
was used to correlate the amide peaks with Cα and Cβ of the preceding residue 
(Figure 3.6B). The amide peaks were linked together based on the connectivity and 
then fitted into the polypeptide sequence of the protein based on the characteristic Cα 
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and Cβ shifts of certain amino acid residues. For example, Cβ chemical shifts of 
serine and threonine residues have higher values than their Cα chemical shifts. Since 
Cβ cross peak would appear as a negative peak in HNCACB, serine or threonine can 
be easily identified among the amide strips (Figure 3.6A). Alanine residues can also 
be easily distinguished since its Cβ chemical shifts are usually below 20 ppm, much 
lower than other residues. Glycine residues have only Cα cross peak in its amide strip 
in HNCACB since its side chain consist of a single hydrogen atom.  
 
 Based on the connectivity given by these two experiments and the knowledge 
of the protein sequence, all backbone amide peaks of Der f 13 have been identified 
and the sequential assignment of peaks in the 1H-15N HSQC is shown in Figure 3.5. 
The strip plots showing sequential assignment of a short stretch of residues from Lys-
9 to Glu-18 is shown in Figure 3.6. The sequential assignment of Cα and Cβ chemical 
shifts of all residues is also completed. 
 
 In order to obtain the remaining chemical shifts of the side chain carbon, 
CC(CO)NH experiment was employed. Each amide strip in CC(CO)NH provides the 
correlation between the amide of a particular residue with all the aliphatic side chain 
carbon chemical shifts of the preceding residue (Figure 3.7). Since the backbone NH, 
Cα and Cβ chemical shifts of all residues have been sequentially assigned, the rest of 
the side chain carbon chemical shifts are readily assigned. CC(CO)NH also allowed 
cross-checking of the previous sequential assignment as each amide strip revealed the 
number of side chain carbon atoms which is characteristics for certain types of amino 
acid residues. H(CCO)NH was used to obtain the side chain proton chemical shifts as 
it correlates amide peak with protons from the preceding residue. HCCH-TOCSY 
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experiment provided the linkage between side chain carbon to its proton. The 
assignment of all chemical shifts has been deposited at the BioMagResBank 





Figure 3.4. One dimensional 1H-NMR of Der f 13. Good dispersion of peaks at the 
amide region and methyl region indicates that Der f 13 is a well folded protein. 
Spectrum was recorded using the Bruker AVANCE 500 MHz NMR spectrometer 
equipped with cryoprobe at 298 K. Der f 13 protein sample was in 50 mM acetate 




Figure 3.5. 1H-15N HSQC of Der f 13. All amide cross-peaks of Der f 13 in the 
HSQC spectrum were well resolved and have been successfully assigned sequentially. 
The peaks were labeled accordingly with their respective type and sequence of 
residues in the protein polypeptide chain. 
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Figure 3.6. Sequential assignment of backbone chemical shifts of Der f 13. A. 
Strip plots of HNCACB experiment, showing amide strips with Cα and Cβ 
resonances of the same residue from residues Lys-9 to Glu-18. Negative peaks 
correlated to Cβ resonances are displayed in red. B. CBCA(CO)NH experiment 
showing amide strips correlating Cα and Cβ resonances of the preceding residue. The 




Figure 3.7. Side chain 13C chemical shifts. All side chain 13C chemical shifts were 
derived from C(CO)NH experiment. Correlated 13C peaks of the preceding residue are 




3.2.2.1 Stereospecific assignment of methyl groups 
 
The stereospecific assignment of methyl groups is important in determining high 
resolution solution structure as many long range NOEs can only be derived from the 
side chain methyl groups. The stereospecific assignment can be carried out by 
observing the different splitting pattern in the proton-decoupled 1H-13C HSQC 
experiment using a 10% 13C labeled sample (Szyperski et al., 1992). The 
stereospecificity of methyl groups of valine, leucine and isoleucine can be determined 
based on their splitting patterns as described in Figure 3.8 below. Most methyl groups 





                   Carbon-13 dimension 
 
Figure 3.8. Splitting pattern of different methyl groups. Distinct splitting patterns 
of methyl groups were used as basis to assign different resonance to the spin system. 
Val-γ1, Leu-δ1, Ala-β, Ile-γ2 






Figure 3.9. 1H-13C HSQC spectrum of Der f 13. Experiment was recorded using a 
10% 13C-labeled sample at 298 K temperature. Stereospecific assignments of methyl 
groups were based on the different splitting patterns at the 13C dimension and were 
labeled accordingly in the spectrum. 
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3.2.2.2 Chemical shift index 
 
After sequential assignment, Chemical Shift Index (CSI) can be used to determine the 
secondary structure of the protein and the boundaries of each secondary structure 
element. CSI can be calculated from the deviation of the experimental Cα and Cβ 
chemical shift values against the random coil values for each specific type of amino 
acid, as shown by the following formula: 
             CSI = (Cα - CαRC) - (Cβ - CβRC) 
 
Cα and Cβ are experimental chemical shifts of C-alpha and C-beta, while CαRC and 
CβRC are the standard random coil chemical shift values of C-alpha and C-beta of the 
same type of amino acid. A positive value would represent an α-helix secondary 
structure while negative value would represent a β-strand region (Wishart et al., 1992 
and Wishart et al., 1995).  
 
The CSI plot for Der f 13 is shown in Figure 3.10. As shown in the figure, Der 
f 13 is composed of 10 β-strands and two N-terminal α-helices. The N-terminus is 
lead by a β-strand of approximately eight residues followed by the two adjoining α-
helices and then another 9 β-strands. This is characteristic of the typical secondary 
structure of other FABP structures that have been solved previously. All the 
secondary structure elements were separated by very tight turns or loops, with 






Figure 3.10. Chemical shift index of Der f 13. CSI was calculated based on the 
deviation of Cα and Cβ chemical shifts from the random coil values. The secondary 
structures represented by the CSI plot are shown on top of the figure. An arrow 
illustrates a β-strand while a cylinder illustrates an α-helix secondary structure.  
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3.2.3 Hydrogen bond restraints and TALOS torsion angle restraints 
 
Both hydrogen bond restraints and TALOS torsion angle restraints were used to 
provide additional restraints for the calculation of the structure. Hydrogen bond 
restraints were derived from the hydrogen-deuterium exchange experiment. A total of 
74 peaks were remained in the HSQC spectrum after 4 hours of exchange into 
deuterated buffer in 99.9% D2O (Figure 3.11) and these amide protons are likely to be 
involved in forming hydrogen bonds. Based on the secondary structure predicted 
using CSI, hydrogen bond distance restraints can be determined and added during 
calculation of the structure.  
 
 The TALOS program utilized the sensitivity of the backbone atom chemical 
shifts to local conformation to predict the torsion angles phi (φangle) and psi (ψ 
angle) (Cornilescu et al., 1999). By using the amino acid sequence information and 
chemical shift values of Cα, Cβ, C', Hα and 15N, TALOS program will search its 
database for similar amino acid triplets with the closest similarity in secondary 
chemical shifts and amino acid sequence. If the similarity is high in the database, 
TALOS will predict the torsion angles phi and psi for the particular residue to be used 
during structure calculation. For Der f 13, only torsion angles predicted for region 
with well-defined secondary structure were used for further calculation. Chemical 
shifts of Cα, Cβ, Hα and 15N of Der f 13 derived from 3D experiments described 
previously were used for the prediction in TALOS. Several torsion angles with low 





Figure 3.11.  Hydrogen bond restraints derived from hydrogen-deuterium 
exchange experiment. Two-dimensional 1H-15N HSQC experiment was carried out 
after the Der f 13 was exchanged into buffer in 99.9% D2O for 4 hours. Hydrogen 
bond restraints were derived from peaks remaining in the HSQC spectrum.   
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3.2.4 Automated NOE assignment by CYANA 
 
CANDID module in the CYANA program was used to carry out automated NOE 
assignment by using the inputs of chemical shift list of all assigned resonances and 
the lists of 15N-edited and 13C-edited NOE peaks. However, the direct usage of 
CYANA program may generate scores of ambiguously assigned NOE peaks, and 
hence giving error prone results. Therefore, NOE assignment was carried out first by 
assigning unambiguous NOE cross peaks manually. The assignment of long range 
amide proton NH-NH NOEs was especially useful in generating the spatial 
connectivity. Since Der f 13 is mainly a β-sheet protein, many long range NH-NH 
NOEs can be observed between two adjoining β-strands forming the β-sheets. 
Besides connection between the amide protons, inter-strands NOEs between NH and 
Hα and between methyls are particularly important to define the β-sheets and the 
overall conformation of the protein. For the α-helical region, several β from Hα(i) to 
NH(i+3) were unambiguously assigned and used for the structural calculation. NOE 
peaks that have been unambiguously assigned manually were used as a reference to 
assist the CYANA program to further assign the remaining NOE peaks during the 
calculation. 
 
 A total of 2299 NOEs have been assigned by both manual assignment and 
automated assignment by CYANA (Table 3.1). The connectivities of short range and 
medium range NOE are shown in Figure 3.12. Most of the NOEs assigned were intra-
residue NOEs and sequential NOEs. A substantial number of 560 NOEs were long 
range NOEs.  The NOE assignments of two amide protons in the 15N-edited NOESY 
spectrum are shown in Figure 3.13. Residue Asp-21 is from the α-helical region, and 
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its amide proton has shown typical α-helical NOE cross-peaks pattern in the 15N-
edited NOESY. Several NH-NH NOEs were observed for residues Leu-20 and Lys-
22, as well as several other NOEs between NH of Asp-21 and Hα from Asp-21, Leu-
20 and Phe-19. For residue Val-93, several long range NOEs connecting other protons 
in adjoining β-strands were observed. For instance, long range NOE cross-peaks with 
amide protons from residues Gln-85 and Glu-87 together with Hα from Lys-86. 









Figure 3.12. Short and medium range NOEs. NOEs were derived from 15N-edited 
NOESY and 13C-edited NOESY. All NOEs were either assigned manually or by using 





Figure 3.13. Assignment of 15N-edited NOESY. Figure shows amide strips from 
15N-NOESY spectrum with its peaks specifically assigned. Residues Asp-21 and Val-
93 were shown as representatives for residues in α-helix and β-strand respectively.  
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3.2.5 Calculations of protein structure by CYANA and DYANA 
 
Solution structure of Der f 13 was determined based on the NOE restraints, TALOS 
angle restraints and hydrogen bond restraints. All assigned NOE distance restraints 
from CYANA were used in further structure calculation in DYANA by using 
standard torsion angle dynamics protocol. In total, 2299 NOE distance restraints, 92 
hydrogen bond distance restraints and 132 dihedral angle restraints have been used for 
the calculation in CYANA and DYANA (Table 3.1). The final CYANA target 
function was 1.55, while the backbone R.M.S.D and all atom heavy atom R.M.S.D. 
were 0.59 Å and 1.16 Å respectively. Ten best conformers with lowest target function 
values were used for further energy minimization in AMBER (Pearlmann et al., 
1995). Final ensemble of 10 best structures was checked using Procheck-NMR 
(Laskowski et al., 1996) and coordinates were deposited in Protein Data Bank (PDB 
code: 2A0A). 
 
 The solution structure of Der f 13 resembles closely the typical overall fold of a 
FABP family protein. The N-terminal region of the protein is composed of a β-strand 
(β1) followed by a helix-turn-helix motif consisting of two short α-helices (α1 and 
α2). This is followed by another nine anti-parallel β-strands (β2-β10), which join the 
β1 strand at β10 to form a β-barrel (Figure 3.14 and Figure 3.15). The β-barrel was 
held by strong hydrogen-bonding interactions formed by the 10 anti-parallel β-
strands, thus forming a large hydrophobic core within the β-barrel. Most of the side 
chains pointing into the hydrophobic core are made of hydrophobic residues side 
chains, such as leucine, isoleucine, valine and phenylalanine (Figure 3.16B).  
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The molecular surface of the Der f 13 is highly charged, owing to the fact that 
the the protein consists of high proportion of both positive and negative charged 
residues. Figure 3.16A shows the electrostatic potential distribution on the surface of 
the protein as plotted using the software MOLMOL (Koradi et al., 1996). On one side 
of the protein surface that consists of β-strands β1-β4, there are two large patches of 
positively and negatively charge residues (left diagram, Figure 3.16A). The positively 
charged area is made of residues Lys-7, Lys-9, Lys-34, Lys-37, Arg-52 and Lys-58 
while the negatively charged area is comprised of Glu-5, Glu-41, Glu-45, Asp-47 and 
Glu-61. However, the distribution of charged surface is quite equal on the opposite 
side of the protein (right diagram, Figure 3.16A). Four charged residues were also 
highly exposed on the helix α1 and they are Asp-17, Glu-18, Asp-21 and Lys-22. 
Interestingly, there are two positively charged residues, Arg-106 and Arg-126, with 
their side chains pointing towards the hydrophobic core of the protein.  
 
The solution structure of Der f 13 fitted well with the solved solution structure 
of human brain FABP (Rademacher et al., 2002), which has one of the highest 
sequence similarity with Der f 13. The backbone carbon Cα tracing between the two 
structures fitted nicely with backbone atom R.M.S.D. of 3.13 Å. Most of the 
variations between the two structures are at the two α-helices as well as at some loop 
and turn regions. The two α-helices of the Der f 13 seems to pack closer to the β-
barrel compared to those in human brain FABP. The turn regions between β3-β4 and 
between β7-β8 are also quite different between these two structures. Nevertheless, the 
solution structure of Der f 13 is in good agreement with most of the structures of 






Restraints Used for Calculation  
Total NOE restraints        
Intraresidue,        
Sequential, |i-j| = 1         
Medium range, |i-j| ≤ 4        
Long range, |i-j| ≥ 5 
Hydrogen bond distance restraints 









CYANA target function  
Maximum violation for upper limits (Å)  
Maximum violation for torsion angles (degree)  
AMBER energies (kcal/mol)  
Total energy  
Ramachandran statistics (%)  
Most favored  
Additionally allowed  
Generously allowed  
Disallowed  
Root mean square deviation from mean structure (Å)  
Backbone atoms (residues 6 - 131)  
All heavy atoms (residues 6 – 131) 
1.55 +/- 0.48 
0.32 +/- 0.09 
2.75 +/- 0.84 
 







0.59 +/- 0.08 
1.13 +/- 0.09 
 









Figure 3.14. Secondary structure topology of Der f 13. Each secondary structure is 
numbered (β1-β10 and α1-α2) while end terminal residues of each secondary 
structure are indicated. α-helices and β-strands are represented with cylinders and 





Figure 3.15. Solution structure of Der f 13. A. Stereoview diagram showing 10 best 
superimposed structures of Der f 13. B. Ribbon diagram of Der f 13 solution structure. 








Figure 3.16. Surface diagram and hydrophobic core of Der f 13. A, Surface 
diagram of Der f 13 showing electrostatic potential distribution contributed by 
positively charged (blue) and negatively charged (red) residues. The orientation of the 
left molecule is similar to that in Figure 3.15B. B, Side chains forming the 
hydrophobic core of Der f 13 were shown as green sticks. C, Wireframe backbone 
diagram showing the best fitting between Der f 13 (blue) and human brain FABP 






3.3 Sequence analysis and putative IgE epitope prediction 




We have carried out skin prick test and IgE binding assay to determine whether 
human FABPs are able to bind to IgE or to elicit allergenic reaction symptoms. These 
tests were important as although patients should be immunologically tolerant against 
human FABP, human FABP and Der f 13 might share cross-reactive epitopes as 
shown in manganese superoxide dismutases (MnSOD) from both Aspergillus 
fumigatus and human (Crameri et al., 1996 and Fluckiger et al., 2002). Written 
consent was obtained prior to the skin prick tests. GST-Der f 13 and Der p 2 allergens 
have been tested while another two human FABPs, adipocyte and heart FABPs have 
also been included. (Der p 2 was expressed and purified by a fellow student, Kavita 
Reginald). Buffer controls (PBS and acetate buffer) and histamine control have been 
included as negative and positive controls respectively. GST protein was also 
included as negative control as the Der f 13 construct used in this study is GST-
tagged. 
 
Out of 31 volunteers tested, only 2 of the patients elicited a positive skin prick 
test against Der f 13 (Figure 3.17 and Table 3.2). This low prevalence is not 
surprising as Der f 13 is not a major allergen, while all volunteers have not been 
tested for reaction against crude dust mite extracts. Although the 2 patients, D2 and 
H3 were tested positive for Der f 13, no positive reactions were observed against both 
human FABPs for all the patients in this study group. There were 15 patients tested 
positive for Der p 2, a major dust mite allergen by skin prick experiments. 
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Interestingly, both patients that reacted against Der f 13 have also developed positive 
skin prick response against Der p 2.  
 
Although both adipocyte and heart FABPs do not elicit a positive skin prick 
reaction, there could be a scenario where human FABPs may still be able to cross-
react and bind to IgE, but without cross-linking the IgE receptors on mast cells. Thus, 
we have carried out the IgE ELISA experiments to measure the binding of IgE to Der 
f 13 and human FABPs. Sera from patients D2 and H3, both are Der f 13 positive, 
were used for the IgE assay. It was shown that sera of patients D2 and H3 contain IgE 
that are specific against Der f 13, while no IgE binding was observed against the 3 
human FABPs tested, including adipocyte, brain and heart FABPs (Figure 3.18). 
Thus, these experiments have revealed that although human FABP and Der f 13 share 
significant similarity in their protein sequences, human FABPs do not bind to IgE or 
cross-link IgE receptor on mast cells. 
 
 
 Diameter of wheal and erythema (in brackets), in millimeters 
Patients Histamine PBS buffer GST 
GST- 











D2 4 (7) - (-) - (-) 3 (5) - (-) - (-) 3 (12) - (-) 
H3 5 (21) - (-) - (-) 5 (25) - (-) - (-) 4 (12) - (-) 
Overall 
Frequency 31/31 0/31 - (-) 2/31 0/31 0/31 15/31 0/31 
 
Table 3.2. Skin prick test for Der f 13, Der p 2 and human FABP. The wheal and 
erythema diameter measurements of two Der f 13 sensitized patients (D2 and H3) are 
indicated. The overall frequency of positive reactions in this study for all the 31 
volunteers are shown as fractions. 
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Figure 3.17. Skin prick test on patient H3. Development of wheal and erythema is 
shown in this picture for A, histamine; B, GST; C, GST-Der f 13, D, GST-adipocyte 
FABP; E, Der p 2; F, acetate buffer; G, GST-heart FABP and H, PBS. Human FABP 






Figure 3.18. IgE binding for Der f 13 and human FABP. Human FABP does not 
bind to sera IgE of patients sensitized to Der f 13. The binding of Der f 13 and human 
FABPs to sera IgE were assayed in ELISA experiments using sera from patients D2 
and H3 who are both sensitized to Der f 13. GST was included as a negative control 
as all the proteins used are GST-tagged.  
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3.3.2 Sequence alignment of Der f 13 with human FABPs 
  
To identify putative residues in Der f 13 which may bind to the IgE during allergic 
reaction, we compared the amino acid sequence of Der f 13 with other human FABPs 
that are non-allergenic. All eight known human FABPs were used in this comparison, 
including liver FABP, intestinal FABP, muscle and heart FABP, adipocyte FABP, 
psoriasis-related FABP, ileal FABP, brain FABP and myelin FABP. Several of these 
FABPs have been tested for their IgE binding and skin prick reactivity, and found to 
have negative results for both of these experiments (Section 3.3.1).  
 
 Both BLOSSUM and PAM substitution matrices were used during the 
alignment and both methods provided similar alignment results. The aligned amino 
acids sequences were compared and residues are chosen based on their different 
properties between Der f 13 and human FABP. The selected residues also have to be 
exposed on the surface residue based on the NMR solution structure of the Der f 13 
that has been determined. Based on these criteria, 18 surface residues were identified 
in Der f 13 that are distinctly different than their corresponding residues in human 
FABP. These residues are Glu-5, Lys-7, Glu-11, Lys-12, Lys-15, Asp-21, Lys-22, 
Lys-34, Glu-41, Asn-46, Lys-63, Asp-73, Arg-74, Lys-86, Asp 89, Lys-91, Lys-103 
and Glu-112 and are highlighted in Figure 3.19. Seventeen of these residues are either 
positive or negatively charged residues in Der f 13 while most of their corresponding 
residues in human FABP are either hydrophobic, polar or residues of opposite 
charges. Another residue, Asn-46, is a polar residue while its corresponding residue is 
a conserved glycine residue in human FABPs. From these observations, all the 18 
residues have been selected for site-mutagenesis to determine the IgE binding epitope 
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of the allergen. Solvent accessibility of these residues was also checked with the 
programme, “Naccess” courtesy of Simon Hubbard (University of Manchester) by 





Figure 3.19. Sequence alignment of Der f 13 with human FABPs. Residues shaded 
in gray are surface residues found to have distinct properties between Der f 13 and 
human FABPs and have been selected for mutagenesis studies. Boxed residues are 
those later found to have significantly lower IgE binding when mutated to alanine. 
FABP1, liver FABP; FABP2, intestinal FABP; FABP3, muscle and heart FABP; 
FABP4, adipocyte human FABP; FABP5, psoriasis-related FABP; FABP6, ileal 
FABP; FABP7, brain FABP; and FABP8, myelin FABP. 
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Total Solvent  
Accessibility 
Side Chain  
Accessibility 




Residue Absolute Relative Absolute Relative Absolute Relative 
Glu-5 81.03 47 78.71 58.4 2.31 6.2 
Lys-7 76.35 38 74.48 45.6 1.88 5 
Glu-11 72.74 42.2 72.74 54 0 0 
Lys-12 113.43 56.5 94.71 58 18.72 49.9 
Lys-15 121.27 60.4 111.97 68.6 9.3 24.8 
Asp-21 79.03 56.3 72.07 70.2 6.96 18.5 
Lys-22 24.32 12.1 24.32 14.9 0 0 
Lys-34 158.4 78.9 126.9 77.7 31.5 84 
Glu-41 50.03 29 49.04 36.4 0.99 2.6 
Asn-46 133.76 92.9 109.52 103.1 24.23 64.3 
Lys-63 132.94 66.2 118 72.3 14.94 39.8 
Asp-73 87.78 62.5 75.13 73.2 12.64 33.5 
Lys-86 73.38 36.5 57.11 35 16.27 43.4 
Asp-89 67.64 48.2 56.22 54.7 11.42 30.3 
Lys-91 60.86 30.3 60.86 37.3 0 0 
Lys-103 85.38 42.5 84.43 51.7 0.95 2.5 
Glu-112 60.09 34.9 58.26 43.2 1.83 4.9 
Ser-124# 2.44 2.1 1.73 2.2 0.72 1.9 
 
Table 3.3. Solvent accessibility of residues selected for mutagenesis in Der f 13. 
Solvent accessibility was measured using the programme Naccess. Relative 
accessibility of each residue refers to the percentage of accessibility in comparison 
with the accessibility of that residue type in an extended Ala-x-Ala tripeptide. Alpha 
carbons are categorized as side chain atom and included side chain accessibility 
calculation. IgE epitope residues subsequently identified were highlighted in bold.  
#Residue Ser-124 was not among the residues chosen for mutagenesis, but was 
included in the table for comparison as this residue is highly buried compared to the 
other listed solvent accessible residues. 
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3.4 Site directed mutagenesis, IgE binding ELISA and skin prick 
reactivity 
 
3.4.1 IgE binding ELISA for Der f 13 single mutants  
 
Eighteen single mutants of Der f 13 had been generated and expressed as GST-tagged 
protein. Due to the low prevalence of patients allergic to Der f 13, sera from the two 
patients D2 and H3, who are allergic to Der f 13 were used for initial screening of 
mutants with reduced IgE binding. Selected mutants with reduced IgE binding were 
also further tested in another 4 patients’ sera as described in Section 3.4.2. IgE 
binding was assayed using direct ELISA method with the GST-tagged wild type or 
mutant Der f 13 bound to the solid phase of the ELISA plate. Sera IgE bound onto 
solid phase antigen were detected with biotin conjugated anti-human IgE monoclonal 
antibody followed by avidin conjugated HRP. The degree of IgE binding is 
determined by adding TMB as substrate and measuring the absorbance at 655 nm 
wavelength. All ELISA experiments were performed in duplicates and the results 
were expressed as mean values.  
 
Most of the mutants did not show significant reduction in IgE binding when 
tested using ELISA. However, mutants E41A, K63A, K91A and K103A have shown 
notable reduction in the IgE binding for both patients (Figure 3.20). Among all these 
mutants, K63A was found to have the greatest reduction in IgE binding for both 
patients D2 and H3. For patient H3, the absorbance value for K63A mutant has 
dropped significantly to 1.78 compared to 3.04 for the wild type Der f 13. Reductions 
recorded for E41A, K91A and K103A were much smaller, with their respective 
absorbance values of 2.71, 2.86 and 2.85. Other mutants however did not show any 
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significant reduction in IgE binding. For patient D2, K63A mutant has also shown the 
most significant drop in absorbance value to a value of 1.02 compared to the wild 
type absorbance of 1.50. Mutants E41A, K91A and K103A have also shown reduced 
IgE binding, but less significant as compared to K63A. In addition to these four 
mutants, mutant K12A has also been found to have reduced IgE binding to sera of 
patient D2 with an absorbance value of 1.26. It is interesting to note that for the sera 
of patient D2, several of the mutants have shown increases in IgE binding absorbance 
values, in particularly mutants K15A, K22A and K34A. 
 
  
3.4.2 Reduced IgE binding of double mutants and triple mutants 
 
Four single mutants have been identified to have lower IgE binding when a single 
charged residue was changed to an alanine residue. These residues are Glu-41, Lys-
63, Lys-91 and Lys-103, and they are located on β-strands β2, β4, β7 and β8 
respectively (Figure 3.24). These 4 residues are located at two distinct patches on the 
surface of the Der f 13 molecule. Residues Glu-41 and Lys-63 are located on one side 
of the protein with an inter-residue distance of about 7.8 Å, while residues Lys-91 and 
Lys-103 are another side of the protein with inter-residue distance of 11.5 Å. The 
locations of these residues may suggest that they can form two separate epitopes on 
the surface of the molecule for IgE binding and cross-linking. Thus, we have designed 




The double mutants were tested for their IgE binding reactivities against sera 
from patients D2 and H3. Both double mutants E41A_K63A and K91A_K103A have 
shown greater reduction in IgE binding reactivity compared to those of the single 
mutants (Figure 3.21). The degree of reduction in IgE binding is higher for 
E41A_K63A compared to K91A_K103A, and this observation was consistent with 
earlier findings that E63A single mutant has shown the most significant drop in IgE 
binding compared to other single mutants. To further reduce the IgE binding capacity 
of the protein, a triple mutant combining 3 mutations, E41A, K63A and K91A, has 
been generated and named the ‘3A mutant’. The binding of 3A mutant to IgE from 
sera of both patients D2 and H3 has been further reduced compared to the two double 
mutants (Figure 3.21). Another triple mutant variant with opposite charge 
(E41K_K63E_K91E) was also generated but due to the low solubility and stability 
during purification processes. The change in such characteristics may be due to the 
charge repulsion with neighbouring residues when opposite charged residues were 
introduced. Hence, it was included in further experiments. 
 
 Since the screening for all mutants were initially performed using sera from 
only two patients D2 and H3, further validation of our IgE binding data was 
performed using four additional sera from patients reactive to Der f 13. Two sera were 
from two Singaporeans, S1 and S2, while sera 4Y and 21Y were from another 2 South 
African patients. These sera were tested for their IgE binding to wild type Der f 13; 
single mutants E41A, K63A, K91A and K103A; double mutants E41A_K63A and 
K91A_K103A; and the triple mutant 3A. Overall, the IgE binding profile seemed to 
agree with the ones shown by patients D2 and H3 (Figure 3.21). However, mutant 
E63A is an exception and did not show the lowest IgE binding among the single 
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mutants tested for patients S1 and 21Y. Instead, K103A single mutant showed the 
lowest IgE binding among the single mutants for patients S1 and 21Y. All sera 
showed the lowest IgE binding to the 3A mutant among all the mutants tested 
although a significant amount of binding can still be observed for sera from patient 
S1. 
 
Figure 3.20. IgE binding assay of Der f 13 single alanine mutants. IgE binding of 
single alanine mutants of Der 13 were assayed using ELISA and compared to wild 
type Der f 13 (WT). GST protein was included as negative control. IgE binding was 







Figure 3.21. IgE binding assay for double mutants and triple mutant 3A of Der f 
13. For all patients, except S1, there were significant reductions in IgE binding for the 
double mutants, E41A_K63A and K91A_K103A, and the 3A triple mutant, 
E41A_K63A_K91A, compared with wild type Der f 13. Patients D2, H3, S1, and S2 are 
Singaporeans, whereas patients 4Y and 21Y are South Africans. Do note that the y-axes 
are of different scales and upper limits.  
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3.4.3 Triple mutant 3A cannot inhibit binding of IgE to wild type 
Der f 13 
 
To further validate the reduction in IgE binding of triple mutant 3A, both wild type 
and 3A mutant of Der f 13 were tested for their inhibitory activities on the binding of 
sera IgE from D2 and H3 patients to wild type Der f 13. For both patients, the 3A 
mutant failed to inhibit the binding of IgE to the wild type Der f 13, even up to 50 µg 
of 3A mutant protein were used for inhibition (Figure 3.22). In contrast, wild type Der 
f 13 managed to inhibit up to 100% of the IgE binding when 10 µg of the Der f 13 is 
used for inhibition. This clearly showed that the 3A mutant has lost its IgE binding 
ability when the three epitope residues were removed.  
 
  
3.4.4 Skin prick reactivities of wild type and triple mutant 3A of Der 
f 13 
 
Skin prick tests were carried out to determine whether the 3A mutant is still able to 
cross-link the IgE receptors on the mast cells and release pro-inflammatory mediators. 
Skin prick tests were carried out as described in Section 2.4.3. The diameters of the 
wheal and erythema were used to determine the skin prick reactivity induced by the 
wild type and 3A mutant of Der f 13. Only wheal with a diameter of 3 mm or more is 
considered to be positive skin prick result. Table 3.4 showed that the skin prick 
reactivity of the 3A mutant of Der f 13 has been greatly reduced when compared to 
the wild type Der f 13 and histamine positive control. These results further suggested 
 115 
that the IgE binding epitope of 3A mutant has been abolished and its ability to cross-





Table 3.4. Skin prick test of 3A mutant. The 3A mutant has shown significant 
reduction of skin prick reactivity compared to wild type Der f 13. One plus sign (+) 
represents a marginal positive reaction (wheal and erythema diameter of at least 4 mm 
and 20 mm respectively, whereas two plus signs (++) refer to a reaction similar to that 
observed for histamine control. Negative sign (-) denotes negative reaction with 




Figure 3.22. Inhibition of IgE binding by wild type and 3A mutant of Der f 13. 
The IgE binding to Der f 13 was inhibited in both patients by wild type Der f 13 (), 
but not by the 3A mutant ().  
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3.4.5 Circular dichroism and gel filtration chromatography of wild 
type and 3A mutant of Der f 13  
 
To examine whether reduction of the IgE binding and skin prick reactivity of the 3A 
mutant were due to the loss of epitope residues or the disruption of the structure of the 
protein, circular dichroism experiments were carried out to compare the secondary 
structure of wild type and 3A mutant of Der f 13. The far-UV CD spectrum of Der f 
13 showed a typical β-sheet structure with a single minimum peak at 218 nm and 
another maximum at 195 nm. The CD spectrum of the 3A mutant resembled that of 
the wild type Der f 13, with similar wavelengths and intensities for the maximum and 
minimum peaks (Figure 3.23A). Hence, the overall secondary structure of the 3A 
mutant was relatively unchanged and similar to that of the wild-type Der f 13 protein. 
Gel filtration chromatography also showed that the 3A mutant eluted at a similar 




3.4.6 IgE binding epitope site on Der f 13  
 
By combining the results of IgE epitope mapping and the solution structure of Der f 
13, we are able to determine the IgE binding sites on the structure of Der f 13. All the 
four epitope residues are coincidently charged residues and highly exposed on the 
surface of the protein. These residues can be grouped into two patches based on their 
proximity to each other, with residues Glu-41 and Lys-63 on one side of the protein, 
while Lys-91 and Lys-103 on the opposite side. All four epitope residues are located 
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on the β-barrel with residues Glu-41, Lys-63, Lys-91 and Lys-103 residing on β-
strands β2, β4, β7 and β8 respectively. These four residues are also highly conserved 
in several other known group 13 allergens including Blo t 13, Tyr p 13 and Lep d 13, 
except for residue Lys-103 which is replaced by a threonine residue in Tyr p 13 





Figure 3.23. Circular dichroism and gel filtration profiles of the wild type and 
3A mutant of Der f 13. A, Far-UV CD spectra of wild type () and 3A mutant () 
of Der f 13 demonstrated that both proteins are a typical β-sheet protein with 
minimum peak at 218 nm.  B, Gel filtration chromatogram showed that both wild type 
Der f 13 (solid line) and 3A mutant (broken line) do not aggregate and eluted at 








Figure 3.24. IgE binding epitope residues of Der f 13. A, Four charged residues, 
Glu-41, Lys-63, Lys-91 and Lys-103 involved in IgE binding were shown on a wire 
frame model. B, Surface diagrams showing that the four charged residues are located 
on two opposite sites of the protein. Negatively charged epitope residues are colored 
in red and positively charged epitope residues are colored in blue.  
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3.5 PBMC proliferation and cytokine release 
3.5.1 Isolation of PBMC from group 13 allergic patients 
 
Ficoll-Hypaque technique was used to separate blood mononuclear cells from the 
plasma and red blood cells. After blood samples were added with Ficoll solution, 
centrifugation was performed to separate the components into different layers. Red 
blood cells would sendiment at the bottom of the tube while the plasma layer would 
remain as the uppermost layer. Mononuclear cells will be separated from the red 
blood cells by a thick layer of Ficoll solution. After careful separation and washing 
with RPMI buffer, a 1 ml sample of blood will typically yield around 1 million of 
mononuclear cells. The viability of the cells was checked under light microscope after 




3.5.2 Stimulation of PBMC proliferation by Der f 13 and 3A mutant 
 
PBMCs from patients D2 and H3 isolated from Ficoll-Hypaque technique were 
cultured in supplemented RPMI medium in 96-wells round bottom culture plates. 
Cells were inoculated at 100,000 cells per well and incubated with either wild type or 
3A mutant of Der f 13. After 6 days of incubation, PBMC proliferation was measured 
by using WST-1 (Biovision) colorimetric method to determine the activity of 
mitochondrial dehydrogenase. In general, PBMCs stimulation was observed for either 
the wild type or 3A mutant of Der f 13 and similar levels of proliferation were found 
in patients D2 and H3 as indicated by the stimulation index (Figure 3.25). Compared 
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to patient D2, the overall PBMCs proliferation was actually higher in patient H3, 
whom has also shown a higher IgE binding to Der f 13. The stimulation indexes for 
wild type and 3A mutant stimulated cells of patient H3 were 53.8% and 52.1% 
respectively, while the stimulation indexes for patient D2 were 22.5% and 23.6% 
respectively. These results suggest that both the wild type and 3A mutant of Der f 13 
were able to stimulate the proliferation of T cells in PBMCs to similar levels and have 





Figure 3.25. PBMC proliferation by wild type and 3A mutant of Der f 13. 
PBMCs from two Der f 13 sensitized patients have shown similar levels of 
proliferation when stimulated with either wild type Der f 13 (striped bar) or 3A 
mutant (empty bar). Proliferation was expressed as stimulation index (%) against 




3.5.3 Cytokines release by wild type and 3A mutant of Der f 13 
 
Although both wild type and 3A mutant of Der f 13 were able to stimulate PBMCs 
from Der f 13-sensitized patients, the type of T-cell proliferated would be of great 
interest as CD4+ T-cells may adopt either a Th1 or Th2 proliferation pathway. Instead 
of the usual CD4+ T cells, T-regulatory (Treg) cells may be stimulated to proliferate 
instead. The mode of proliferation can be determined by measuring the types of 
cytokine being produced by PBMC cells after stimulation with either the wild type or 
3A mutant of Der f 13. Supernatant of PBMC cultures were harvested after incubation 
with the wild type or 3A mutant of Der f 13, and levels of different cytokines 
produced were measured. In our cytokine assays, the levels of IL-2, IL-4, IL-5, IL-10, 
IL-12, IL-13, IFN-γ, GM-CSF and TNF-α cytokines were measured by using the 
Bioplex cytokine assay (Bio-Rad). Cytokines secreted by Th1 cells were represented 
by IL-2, IL-12 and IFN-γ; while typical cytokines from Th2 cells were IL-4, IL-5 and 
IL-13. The cytokine IL-10 is used as an indicator for T regulatory cells proliferation. 
TNF-α and GM-CSF are both cytokines involved in the inflammation of airway and 
also implicated in inflammatory symptoms in other diseases (Lukacs, 1995 and Hui-
Yuen, 2006). The levels of cytokines were compared between PBMC cultures 
stimulated with either wild type or 3A mutant of Der f 13 from the same patient.  
 
In general, both patients D2 and H3 showed decreased levels of Th2 cytokines 
secreted by PBMCs when stimulated with the 3A mutant. As shown in Figure 3.26, 
the levels of IL-5 and IL-13 are much lower when stimulated with the 3A mutant 
compared to those stimulated with the wild type Der f 13. PBMCs from both patients 
D2 and H3 released increased levels of IL-5 and IL-13 when stimulated with the wild 
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type Der f 13, with patient D2 showing the most drastic increase in levels of both 
cytokines. These results are not surprising as both patients are already sensitized to 
Der f 13 and therefore their T cells should show a strong Th2 response against Der f 
13. In addition, the levels of IFN-γ secreted by PBMCs of both patients are very low 
when stimulated with wild type Der f 13. This further proved that Der f 13 stimulates 
a Th2 response, in which IFN-γ is a strong inhibitor. However, secretion of another 
cytokine, IL-4, commonly found in Th2 cells was not detected when the PBMCs were 
stimulated by either wild type or 3A mutant of Der f 13.  
 
 In contrast, PBMCs stimulated with the 3A mutant showed higher level of 
IFN-γ compared to that stimulated with wild type Der f 13 (Figure 3.26). Both 
patients D2 and H3 showed increased levels of IFN-γ, with the former patient 
showing more than 10-fold increase in the level of secretion. This observation is 
accompanied by simultaneous reduction in the level of IL-13 secretion, further 
supporting the notion that the 3A mutant of Der f 13 has shifted the T-cell 
proliferation from a Th2 to a Th1 pathway. Interestingly, it was also observed that 
level of the Th1 cytokine, IL-2, was increased in the PBMCs of patient D2 when 
stimulated with wild type Der f 13. This agrees with the function of IL-2 that it may 
be involved in the induction of T-cells for the secretion and gene transcription of IL-5 
(Mori et al., 1995 and Mori et al., 1996). IL-5 has been shown to be involved in the 
infiltration of eosinophils among asthmatics (Hamid et al., 1991 and Mori et al., 
1996) and the levels of IL-5 seemed to be increased in both patients’ PBMCs 
stimulated with the wild type Der f 13.  
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The cytokine IL-12 has been shown to reduce the number of eosinophils and 
induce apoptosis in eosinophil (Bryan et al., 2000 and Nutku et al., 2001). IL-12 was 
not detected in PBMCs of both patients stimulated with wild type or 3A mutant of 
Der f 13. Such a low level of detection may also be due to assay error but not the 
absence of this cytokine during stimulation. The secretion of IL-10 appeared to be 
only significant in patient D2 when the PBMC was stimulated with wild type Der f 
13. This is surprising as IL-10 is a cytokine released by regulatory T-cells and 
normally function to inhibit Th2 cells and its cytokine release. The other signature 
cytokine of regulatory T cells, TGF-β, was not detected in these assays.  
 
The cytokines TNF-α and GM-CSF are both involved in the activation of 
eosinophils and elevated levels have been detected in the airways of asthmatics and 
asthmatic mouse model (Broide et al., 1992 and Cates et al., 2004). Interestingly, 
stimulation of PBMC with the 3A mutant of Der f 13 has increased the levels of these 
two cytokines compared to those for wild type Der f 13. This is especially apparent in 
patient D2 where both cytokines appeared to be stimulated by the 3A mutant, while 
only GM-CSF was stimulated in patient H3. It appears that although several of the 
Th2 cytokines have been down-regulated, but there is a concurrent increase in the 
secretion of inflammation cytokines such as TNF-α and GM-CSF when the PBMC of 
patient D2 was treated with the 3A mutant. 
   
 In conclusion, the increased levels of IFN-γ and decreased levels of IL-5 and 
IL-13 secretion suggest that the 3A mutant of Der f 13 can act to shift the T cell 
response of a patient allergic to Der f 13 from a Th2 to a Th1 type. As also discussed 
above, the shifting from Th2 to Th1 cytokine pathway by the 3A mutant is more 
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remarkable in patient D2 compared to H3. In patient D2, the increased level of IFN-γ 
and the decreased in level of IL-13 are much more significant in contrast to those of 
patient H3. This suggests that patient D2, who had lower a IgE binding to Der f 13 
could switch from a Th2 to a Th1 cytokine profile more effectively than patient H3 
when treated with the hypoallergenic 3A mutant of Der f 13.  However, pro-
inflammatory cytokines TNF-α and GM-CSF, were also induced by 3A mutant in 
both patients D2 and H3 while the level of Treg cytokine, IL-10, was not elevated.  
 
Since the recombinant proteins used in these experiments were not treated to 
remove any contaminations with bacterial components such as lipopolysaccharide 
(LPS), it was important to consider the effects of such contamination as they might 
affect the T-cell proliferation. However, the cytokine profile here showed that Der f 
13 and 3A mutant stimulated strikingly different pathways, with Th2 and Th1 
pathways respectively. This observation is clearly anticipated, as both patients are 
allergic against Der f 13 and stimulation of lymphocytes with wild type allergen 
would trigger a Th2 pathway. Both recombinant proteins were also similarly purified 
to high purity using two steps chromatography, thus reducing contamination from 







Figure 3.26. Cytokine release profile of PBMC stimulated with wild type or 3A 
mutant of Der f 13. PBMCs stimulated with 3A mutant (empty bar) showed an 
increased  secretion of IFN-γ, a marker for Th1-type proliferation, in both patients D2 
and H3. Stimulation with wild type Der f 13 (solid bar), however resulted in increased 
production of IL-5 and IL-13, which are cytokines typical of Th2-type proliferation. 
Note that the vertical scales are different between 2 plots. 
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3.6 Mouse immunization and generation of IgE blocking IgG 
3.6.1 IgG and IgE production from mice immunized with wild type 
or 3A mutant of Der f 13 
 
The amount of IgG and IgE produced during the course of mouse immunization was 
measured by ELISA experiments using antibodies specific against mouse IgG and 
mouse IgE respectively. The average titer (each for IgG and IgE) for 5 mice from 
each group immunized with either wild type or 3A mutant of Der f 13 is shown in 
Figure 3.27. The titer of IgG antibodies increased throughout the 4th week and 6th 
week (second and third injection) and the highest amount of IgG was detected from 
the 8th week onwards. Similar IgG antibodies production was observed for both sets 
of mice immunized with either the wild type Der f 13 or 3A mutant. The IgE titer did 
not increase much compared to that of IgG, even for the wild type Der f 13 
immunized mice. This, however, could be due to the low levels of IgE in the mouse 
blood circulation and the limited sensitivity of this ELISA experiment. This 
observation could also be due to the inability of the mouse to be sensitized with the 




3.6.2 3A mutant raised IgG blocks binding of human IgE to wild 
type Der f 13 
 
The mouse sera were tested for the ability of their IgG to block the binding of patient 
sera IgE to wild type Der f 13. To evaluate the inhibitory effect of the IgG raised on 
IgE binding, mouse antisera from both immunization groups were assessed with 
inhibition ELISA using pooled human sera from patients D2 and H3. Mouse sera 
from both wild type and 3A mutant of Der f 13 immunization groups were able to 
inhibit the binding of IgE to Der f 13 at a fairly similar level. All mouse sera showed 
an inhibition percentage of at least 60%, whereas a couple of the immune sera from 
each group could inhibit IgE binding up to 80% (Figure 3.28). As a control, sera from 
the control mouse (immunized with buffer and adjuvant) were unable to block the 
binding of patient IgE to Der f 13. These results suggest that sera IgG from mice 
immunized with either the wild type Der f 13 or 3A mutant are able to act as blocking 




Figure 3.27. Mouse IgG and IgE titer. The IgG and IgE titer was measured 24 hours 
after immunization with either wild type (solid square) or 3A mutant (open triangle) 
of Der f 13. Mouse IgG titer are represented by solid lines and IgE titer are 




Figure 3.28. Inhibition of human IgE binding to Der f 13 by mouse blocking IgG. 
Inhibition ELISA studies were performed using sera from mouse immunized with 
either wild type (WT1-5) or 3A mutant (3A1-5) of Der f 13. Significant inhibitions 
were observed for both sets of mouse sera on binding of patient IgE to wild type Der f 
13. Serum from mouse immunized with buffer was included as control.  
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3.6.3 Binding of mouse sera IgG to other group 13 isoforms. 
 
The mouse sera IgG raised with wild type or 3A mutant of Der f 13 were also tested 
for their cross-reactivities with other group 13 allergen isoforms identified from EST 
experiments (Ong, 2003). These group 13 isoforms included DF1096, from D. farinae 
and BT796 and BT1694 from B. tropicalis. Interestingly, the mouse IgG from both 
groups of mice could selectively bind to these isoforms to certain degree, with the 
strongest binding to BT796 (Figure 3.29). This is not surprising as Der f 13 and 
BT796 shares the highest sequence identity and similarity, of 79% and 89% 
respectively. This showed that the blocking IgG raised might be useful against not 
just Der f 13, but also other group 13 allergens.  
 
 
3.6.4 Binding of mouse sera IgG to human FABP 
  
The binding of raised mouse sera IgG to human FABP was assessed to determine 
whether IgG would cross-react with human FABPs. Three human FABPs, including 
adipocyte FABP, brain FABP and heart FABP were used to examine their binding to 
pooled mouse sera IgG. None of the human FABP tested show significant binding to 
the mouse IgG, indicating that the IgG raised were specific against Der f 13 or its 








Figure 3.29. Binding of mouse IgG to Der f 13, other group 13 isoforms, and 
human FABPs. Two sets of sera from mouse immunized with either wild type (solid 
bar) or 3A mutant (open bar) of Der f 13 were used. Both sets of mouse sera bind to 
Der f 13 and other group 13 isoforms to certain degree, but failed to bind to human 





3.7 Hypoallergen immunotherapy: Th1 or Treg? 
 
The primary target of specific immunotherapy against allergy is to prevent the 
progression of the T-cell proliferation into Th2 type, which produces cytokines that 
enhance release and synthesis of IgE as well as the development of effector cells. We 
have observed an overall shift from Th2 to Th1 type proliferation when we stimulated 
PBMC from Der f 13 allergic patients with the hypoallergenic 3A mutant. Although 
Th1 cells produce Th1 cytokines that has strong inhibitory effect on the growth of 
Th2 cells and thus secretion of Th2 cytokines, there are also concerns that Th1 cells 
could also involve in Th1-mediated autoimmune diseases and in the effector phase of 
allergic diseases (Veldman et al., 2006; Akdis et al., 2005). Recently, regulatory T 
cells (Treg) have been implicated to play an important regulatory role in the 
peripheral tolerance to allergens (Jutel et al., 2003; Akdis et al., 2005). Treg cells 
produce IL-10 and TGF-β, which are able to effectively suppress the production of 
IgE antibodies while inducing the production of IgG4 and IgA at the same time 
(Figure 3.30). In addition to that, Treg cells are also able to inhibit the development of 
Th2 cells (Jutel et al., 2003 and Akdis et al., 2005). Hence, effector cells such as mast 
cells and basophils will be suppressed as they require Th2 cytokines for priming, 
survival and function.  
 
Treg cells, however, have also shown to be responsible for tumor tolerance 
and chronic infection, probably due to its immunosuppressive functions. Although the 
production of IL-10 may anergize Th1 and Th2 cells, it may also hamper immune 
responses to foreign infections such as Leishmania major, Mycobacterium 
tuberculosis and Plasmodium falciparum (Kane and Mosser, 2001; Boussiotis et al., 
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2000; Plebanski et al., 1999). Besides, inductions of IL-10 and T-cell tolerance have 
been heavily implicated in the progression of tumor cells (Veldman et al., 2006). 
Extreme caution needs to be made during the course of immunotherapy as skewing an 
immune system from Th2 to either Th1 or Treg pathways might lead to other diseases 
circumstances (Figure 3.30). 
 
Studies using peripheral T-cells treated with hypoallergen preparations have 
yielded mixed and sometimes debatable results as suppression of the Th2 cells can 
lead to either an increase of Th1 or Treg cytokines production (Jutel et al., 1995 and 
Akdis et al., 2005). Interestingly, grass pollen immunotherapy carried out by 
Wachholz et al. (2002) has shown that the reduction in levels of Th2 cytokine was 
only detected at the local nasal area, but not at the circulating PBMCs. The 
differences in the reaction observed between local inflammation area and peripheral 
cells could be due to the varying repertoire of immune cells as the active cells of an 
allergic immune response may not be physically located in the peripheral blood but 
only localized in the inflammation area instead (Wachholz et al., 2002 and Holm et 
al., 2004). Therefore, careful conclusions need to be made when testing 




Figure 3.30. Regulation of T-cells during immunotherapy. The suppression of Th2 
cells is carried out by either Th1 or Treg cells during the allergy specific 
immunotherapy. Both Th1 and Treg cells produce cytokines that suppress 
proliferation of Th2 cells while inducing non-IgE antibodies that may prevent allergy 
disease progression. However, imbalance of any of these T cell types may lead to 
development of other immune system related diseases such as autoimmunity, allergy 
or chronic infection and cancer due to immune response suppression. This figure is 
adapted, modified and updated from illustrations and articles found in Kay (2001), 
Akdis et al. (2005) and Veldman et al. (2006).  
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3.8 Charged residues: A preferred epitope residues for IgE? 
 
IgE epitope mapping of Der f 13 has revealed 4 important charged residues, Glu-41, 
Lys-63, Lys-91 and Lys-103, involved in IgE binding. Interestingly, Der f 13 has a 
very high content of charged residues amounting to 36.6% of the total residues and 
most of these charged residues are highly exposed on the surface of the protein. These 
observations lead us to hypothesize that charged residues play a crucial role in IgE 
binding as well as the allergenicity of an allergen. Several epitope mapping studies 
that have been carried out by other research groups will be discussed in this section. 
However, only those examples that used approaches such as site-directed mutagenesis 
and other mapping techniques that do not abolished the structure of the allergen will 
be considered for this review. Methods that employ peptide mapping, truncation 
studies, cysteines or prolines mutations and random peptide phage display technology 
will not be included here as these methods would normally disrupt the native structure 
of the protein. Hence these ‘disruptive methods’ would not be able to directly identify 
the mapped regions as IgE epitope.  
 
 IgE epitope mapping studies on major allergens such as Der p 2 (Mueller et al., 
2001), Bet v 1 (Spangfort et al., 2003), and Hev b 6.02 (Karisola et al., 2004) have 
also revealed the importance of charged and polar residues on IgE binding and cross-
linking (Table 3.5). In epitope mapping of Bet v 1, mutation of a single charged 
residue, Glu-45 to Ser-45 has completely abolished binding of Bet v 1 to a 
monoclonal antibody that cross-inhibits IgE binding to Bet v 1 (Spangfort et al., 
2003). The conserved residue Glu-45 has not only been implicated as an important 
IgE binding residue not just in other major pollen allergens from trees of the Fagales 
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order, but also in other cross-reactive food allergens of the Bet v 1 family such as Pru 
av 1, Mal d 1, and Pyr c 1 (Mirza et al., 2000 and Neudecker et al., 2003). The IgE 
binding epitopes have been mapped to residues Arg-5, Lys-10, Glu-29, Tyr-30, and 
Gln-38 by site-directed mutagenesis in Hev b 6.02. Although there are only 8 charged 
residues in Hev b 6.02, the involvement of charged residues in IgE binding seemed to 
be crucial as 3 of them were highly implicated in IgE binding (Karisola et al., 2004).  
 
 Mueller and co-workers (2001) have used NMR-based hydrogen exchange 
technique coupled with mutagenesis studies to map the IgE epitope of Der p 2 to 
residues His-30, Arg-31, Lys-33, Ser-57, Lys-96, Ile-97, and Glu-102. Lysine 
residues have been heavily implicated for IgE binding in Phl p 5b (C- terminus) as 
shown recently by Gehlhar et al. (2002). IgE binding and skin prick reactivity 
properties of Phl p 5b have been abolished when 10 of its surface exposed lysine 
residues were mutated, without altering the structural integrity of the allergen. 
Similarly, IgE epitope residues mapped to Par j 1.0101 (residues 1-30, from 
Parietaria judaica pollen) were all charged residues including Lys-21, Lys-23, Glu-
24 and Lys-27 (Colombo et al., 1998). 
 
 Der f 13 has shown a relatively high overall percentage (36.6%) of charged 
residues compared with the average of 28.3% in human FABPs, which are non-
allergenic (Table 3.5). A similar trend is also observed in Der p 2 and Der f 2, which 
are comprised of 24.8% and 25.5% charged residues respectively. These values are 
significantly higher than that of 16.6% in the NPC2 protein (Frolov et al., 2003 and 
Ichikawa et al., 2005), which is the most closely related human homologue Der p 2 
and Der f 2. Equ c 1 (Lascombe et al., 2004), an allergenic lipocalin from horse, has a 
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total of 31.9% of charged residues compared to that of 21.5% in human lipocalin 9 
(Suzuki et al., 2004). Allergenic lipocalin from cockroaches, Bla g 4 also contained 
higher percentage of charged residues (26.3%) than its human counterpart, human 
alipoprotein D, which contains 18.3% of charged residues. This trend was 
consistently observed for Bla g 5 and Der p 8, which have higher percentage of 
charged residues compared to the homologous human GST protein (Table 3.5).  
 
 Although most of the human proteins mentioned above have not been tested for 
their IgE binding, we would postulate that the human proteins normally do not bind to 
IgE or at least would not be able to sensitize the patients to produce IgE specific 
against it. The high abundance of charged residues found in major allergens, 
especially when compared with their homologs in human, may indicate that charged 
residues could play an important role in IgE binding and allergenicity of these 
allergens. The presence of charged residues on allergens may contribute to their 
higher protein solubility, which could favor their allergenic properties, or it could 
simply mean that charged residues are more preferable epitopes for IgE recognition. 
There are still no known structural features or conserved sequences that allow us to 
define an allergen based on structural or biochemical characteristics alone so far. Our 
observations, however may suggest that the presence of a high content of surface 




 Lys Arg Basic (%) 
Asp Glu Acidic 
(%) 
Epitope Residues 
Der f 13 18 6 18.3 9 15 18.3 E41,K63,K91,K103 
FABP1 15 2 13.3 4 13 13.3 - 
FABP2 14 7 15.9 8 13 15.9 - 
FABP3 14 4 13.5 11 8 14.2 - 
FABP4 14 6 15.1 11 9 15.1 - 
FABP5 14 6 14.8 8 12 14.8 - 
FABP6 12 2 10.9 5 11 12.5 - 
FABP7 12 5 12.8 10 10 15.1 - 
FABP8 18 7 18.9 5 9 10.6 - 
        
Der p 2a 14 2 12.4 9 7 12.4 H30, R31, K33, S57, K96, I97, E102 
Der f 2 14 2 12.4 12 5 13.1 - 
NPC2 12 1 8.6 6 6 8.0 - 
        
Phl p 5bb 
(C-terminal) 12 0 8.8 5 6 8.0 
K1,K12,K18,K42,K45, 
K56,K66,K90,K100,K135 
Par j 1.0101c 
(a.a. 1-30) 12 8 14.3 7 8 10.7 K21,K23,E24,K27 
Bet v 1d 15 3 11.3 9 14 14.4 E42,N43,I44,E45,G46, N47,G48,G49,P50,G51 
Hev b 6.02e 2 1 6.9 3 2 11.6 R5,K10,E29,Y30,Q38 
        
Equ c 1 11 9 12.5 13 18 19.4 - 
Lipocalin 9 7 10 9.6 8 13 11.9 - 
        
Bla g 4 13 10 12.6 14 11 13.7 - 
Apolipoprotein D 11 4 7.9 7 13 10.5 - 
        
Bla g 5 22 6 13.7 17 12 14.2 - 
Der p 8 17 12 13.2 16 10 11.8 - 
hGST 12 8 9.5 13 10 10.5 - 
        
Blo t 5 14 5 14.1 8 18 19.4 - 
 
 
Table 3.5. Analysis of charged amino acids of major allergens and their human 
homologues. The contents of positively and negatively charged amino acid residues in 
selected major allergens are compared with their human homologues. The allergenic proteins 
are italic and bold faced. Der f 13 is compared with human FABPs (see Figure 3.19 for 
abbreviations), while Der p 2 and Equ c 1 are compared with the homologous human NPC2 
and Lipocalin 9 respectively. All the allergens listed are found to have a higher overall 
percentage of charged residues compared to their homologous human proteins. The residues 
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identified as IgE binding epitope in the listed major allergens listed here are found to be 
mostly charged and polar residues. 
(All allergen sequences were gathered from Allergome database, while all human 
protein sequences were from Genbank) 
 
a Mueller et al., 2001 
b Gehlhar et al., 2006 
c Colombo et al., 1998 
d Spangfort et al., 2003 






Chapter 4: Structure characterization of Blo t 5 
4.1 Protein expression and purification of Blo t 5 
 
Blo t 5 was expressed and purified as a soluble His-tag protein similar to the method 
as described for Der f 13 in Section 2.2. The protein was purified using Ni-NTA 
column, followed by thrombin digestion and gel filtration FPLC. The monomeric 
protein eluted from the gel filtration column (using Superdex 75 PG) as a single major 
peak at an elution volume of 78 ml. The purity of the protein appeared to be high as 
observed on a 15% SDS-PAGE (Figure 4.1). The purified protein was dialyzed 




Figure 4.1. Expression and purification of His-tag Blo t 5. Blo t 5 was expressed as 
soluble protein in E. coli BL21. Lane 1, low molecular weight marker; lane 2, whole 
cell before IPTG induction; lane 3, whole cell after IPTG induction; lane 4, flow-
through from Ni-column; lane 5, eluted protein from Ni-column; lane 6, Blo t 5 after 







Figure 4.2. Gel filtration profile of Blo t 5. Size exclusion chromatography of Blo t 
5 was performed using Superdex 75PG column on an AKTA FPLC system. A single 




4.2 Circular dichroism spectrum of Blo t 5 
 
Circular dichroism experiments showed that Blo t 5 is a well folded protein and 
contain mainly α-helices in its secondary structure. The CD spectrum contains two 
minima at wavelengths 208 nm and 222 nm (Figure 4.3), which are typical for α-helix 
secondary structures. This observation agrees well with previous study on Der p 5 
from D. pteronyssinus which also showed similar CD spectrum at neutral pH (Liaw et 
al., 2001). Based on the CD spectrum, estimation of the percentages of protein 
secondary structure was also carried out using ‘k2d’ software (Andrade et al., 1993) 
and it was shown that Blo t 5 has an all α-helical secondary structure.  
 
 
Figure 4.3. Circular dichroism spectrum of Blo t 5. CD spectrum of Blo t 5 shows 
α-helical secondary structure with minima at around 208 nm and 222 nm.  
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4.3 1D 1H-NMR and 2D 1H-15N HSQC spectra of Blo t 5 
 
All NMR experiments for Blo t 5 were carried out using a 2 mM protein sample in 50 
mM phosphate buffer pH 7.0 with 10% D2O. The 1D 1H-NMR spectrum of Blo t 5 
showed that Blo t 5 is well folded with considerably well-dispersed peaks for an all α-
helical protein. Peaks at the amide region spanned from around 6 ppm to 9.5 ppm, 
while there were no negative peaks at the methyl region below 0 ppm (Figure 4.4). 
Subsequent 2D 1H-15N HSQC spectrum recorded using a 15N-labeled protein also 
showed well-dispersed amide peaks (Figure 4.5). However, a number of overlaps 
were noticeable in the spectrum especially at around 8 ppm region of the 1H 
dimension. These overlaps were not unusual, as an α-helical protein would typically 
display certain degree of overlaps since their amide peaks tend to concentrate around 







Figure 4.4. One dimensional 1H-NMR spectrum of Blo t 5. Spectrum was recorded 
using the Bruker 800 MHz NMR spectrometer at temperature of 298 K. Blo t 5 




Figure 4.5. 1H-15N HSQC spectrum of Blo t 5. Amide cross-peaks of Blo t 5 in the 
HSQC spectrum have been successfully assigned sequentially. However, 6 amide 
resonances from residues Asp-10 to Glu-15 were not found and could not be assigned 
to the peaks in the spectrum.  The peaks were labeled accordingly with their 
respective type and sequence of residues in the protein polypeptide chain. Peaks were 
labeled according to sequence of the new Blo t 5 construct. 
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4.4 Backbone chemical shifts assignment and chemical shift index 
of Blo t 5 
 
Backbone chemical shifts of Blo t 5 were assigned using similar 3D experiments as 
described for Der f 13, except that all experiments were carried out on a Bruker 800 
MHz spectrometer. Amide proton cross-peaks on 1H-15N HSQC of Blo t 5 were 
assigned by correlating amide strips on HNCACB and CBCA(CO)NH, as described 
for Der f 13 in Section 1.7.2 and Section 2.3.1.2.  Some of these connectivities were 
shown in Figure 4.6, where amide strips from HNCACB and CBCA(CO)NH 
experiments of residues from Ile-61 to Gly-66 were connected based on the Cα and 
Cβ chemical shifts. Based on these correlations, amide proton cross-peaks of Blo t 5 
have been identified and assigned sequentially to the amino acid sequence (Figure 
4.5). However, peaks corresponding to residues from Asp-10 to Glu-15 cannot be 
identified and are missing in the HSQC spectrum. This could due to conformational 
exchange of the N-terminal region as some of the peaks associated to N-terminal 
region of Blo t 5 are rather weak. 
 
Chemical shift index (CSI) of Blo t 5 was measured by comparing the 
experimental chemical shifts of Cα and Cβ of Blo t 5 with random coil values as 
described in Section 3.2.2.2.  The CSI plot showed that the N-terminal region of Blo t 
5 from residue Lys-1 to Glu-15 did not contain any secondary structure and may 
represent a very flexible and unstructured region (Figure 4.7). This observation also 
explains why amide proton peaks of residues from Asp-10 to Glu-15 are not detected 
in the HSQC spectrum. Blo t 5 is comprised of three alpha helical regions, separated 
by tight turns of 1 to 3 residues in length. The three helices, α1, α2 and α3, extended 
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from residues 16 to 42, 44 to 75 and 79 to 110 respectively. The occurrence of these 3 
α-helices confirms the earlier prediction that Der p 5 or perhaps group 5 allergens are 
coiled-coil proteins comprised of 3 α-helices (Liaw et al., 2001).  
 
Although the final structure of Blo t 5 has not been solved, the CSI plot of Blo 
t 5 indicates that Blo t 5 consists of 3 α-helices in its structure. These α-helices may 
form a 3 helix-bundle or may even form a coiled-coil structure based on the 
prediction by Liaw et al. (2001) in Der p 5 allergen. Liaw et al. have also shown that 
Der p 5 may undergo structural changes in different pH conditions (as observed in 
circular dichroism studies) and forms large filament-like aggregates at low pH 
condition. Hence, solving the protein 3D structure under various pH conditions would 
be of great interests as it would provide a model for Blo t 5 to form a large coiled-coil 
structure at low pH condition. The aggregation or formation of coiled-coil structures 
of Blo t 5 would involve major conformational changes and thus may affect the IgE 
binding of the protein. Understanding the relationship between such structural 
changes and allergenicity will provide us a new insight and allow us to design new 
strategies for specific immunotherapy against Blo t 5. 
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Figure 4.6. Sequential assignment of backbone chemical shifts of Blo t 5. Strip 
plots of HNCACB experiment (in red frame) showing amide strips with Cα and Cβ 
resonances of the same residue from residues Ile-61 to Gly-66. Negative peaks 
correlated to Cβ resonances are displayed in red. Amide strips from CBCA(CO)NH 
experiment (in black frame) correlate to Cα and Cβ resonances of the preceding 
residue. The connectivities between residues’ Cα and Cβ with their preceding Cα and 
Cβ chemical shifts are shown in dotted lines. 
 
 
Figure 4.7. Chemical shift index of Blo t 5. CSI was calculated based on the 
deviation of Cα and Cβ chemical shifts from the random coil values. Based on the 
CSI values, Blo t 5 is predicted to contain 3 α-helices as shown by the diagram on top 
of the figure. CSI values for residues 10-15 were not shown, as backbone chemical 
shifts of these residues could not be assigned. 
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Chapter 5: Conclusion 
5.1 Structure and IgE epitope mapping of Der f 13 leading to 
development of hypoallergenic mutant 
 
To date, there are still no general characteristics that can be used to identify a protein 
as an allergen. Most of the protein structures solved for allergens reveal that there are 
no common structural features that make a protein allergenic. More interestingly is 
that most of the allergen structures of allergen also share common folds and overall 
structures with their homologous non-allergenic protein. The most important question 
that has been asked for many times in allergen characterization is: ‘what makes 
certain protein to be allergenic, but not the other’, since many of these protein share 
similar structure and protein sequence.  
 
Der f 13 is one of the newly characterized group 13 allergen from dust mite D. 
farinae. What makes Der f 13 a protein of interest in our study is Der f 13 shares a 
high sequence similarity with human FABPs, up to 58.6 % amino acid similarity with 
human brain FABP. Interestingly, human FABPs would not elicit any allergy reaction 
or bind to IgE. Thus, we have taken various approaches to study the structure and 
allergenicity differences between human FABPs and Der f 13 by using NMR, site-
directed mutagenesis and other immunological techniques.  
 
The structure of Der f 13 has been successfully determined using NMR 
techniques with a backbone R.M.S.D. of 0.59 Å and heavy atom R.M.S.D. of 1.16 Å. 
The overall structure of Der f 13 resembles a typical structure of FABP, consisting of 
10 β-strands forming a β-barrel and another 2 α-helices adjacent to it. The structure of 
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Der f 13 overlay well with the solution structure of human brain FABP. The surface 
of the Der f 13 is highly charged due to the dense distribution of charged residues on 
the surface of the protein, as well as the high content of charged residues of the 
protein sequence. The solution structure was used as a reference to identity unique 
surface charged residues that are distinct from human FABPs and could represent 
putative IgE epitope residues.  
 
Based on the sequence alignment with non-allergenic human FABP, we can 
identify putative IgE epitope residues in Der f 13. Site-directed mutagenesis coupled 
with IgE ELISA experiments have proved to be useful in validating the epitope 
residues involved in IgE binding. Reduction in IgE binding can be observed when a 
putative epitope residue is mutated to another type of amino acid. Eighteen unique 
residues have been identified in Der f 13 that are significantly different from the 
corresponding residues in human FABP. Four single mutants E41A, K64A, K91A 
and K103A have been identified from IgE binding screening to have lower IgE 
binding. These residues are located on two patches on the structure of Der f 13 with 
Glu-41 and Lys-63 on one side while Lys-91 and Lys-103 on opposite side of the 
protein. Based on the proximity of these residues, double mutants E41A_K63A and 
K91A_K103A have been constructed and shown to have further reduction in IgE 
binding. The triple mutant 3A with mutations E41A_K63A_K91A has the lowest IgE 
binding and do not inhibit IgE binding to wild type Der f 13. The lost of IgE binding 
ability of 3A mutant is due to the lost of epitope residues and rather than its structural 
integrity. CD spectroscopy analysis and gel filtration have shown that the 3A mutant 
shared similar characteristics as the wild type Der f 13. In addition, IgE epitope 
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residues identified in Der f 13 are also conserved among other group 13 allergens 
from dust mites.  
 
With its IgE binding abolished, 3A mutant proved to be a likely candidate as 
hypoallergen molecule for specific immunotherapy against Der f 13. Skin prick tests 
carried out with patients allergic to Der f 13 showed that skin prick reactivity of 3A 
mutant has been greatly reduced compared to the wild type allergen. The 3A mutant 
also retained its immunogenicities and T-cell epitopes as it was still able to stimulate 
proliferation in PBMC from Der f 13-allergic patients, to a similar level as wild type 
Der f 13. In both patients tested, 3A mutant was able to stimulate an elevated released 
of IFN-γ and reduction in the levels of IL-5 and IL-13. This is in contrast with wild 
type Der f 13 which stimulated an increase in IL-5 and IL-13 and reduction in IFN-γ. 
Hence, 3A mutant proved to be able to switch T-cell proliferation from a Th2 to Th1 
pathway.  However, pro-inflammatory cytokines TNF-α and GM-CSF were also 
increased by the 3A mutant stimulation. Although the IgE epitope residues have been 
removed in 3A mutant, it is still able to raise blocking IgG in mice which able to 
inhibit the blocking of patient sera IgE to wild type Der f 13. With its IgE epitope 
removed and its ability to stimulate Th1 cytokine and blocking IgG production, 3A 
mutant proved to be a potential candidate for specific immunotherapy against Der f 
13.   
 
The identification of the 4 epitope residues Glu-41, Lys-63, Lys-91 and Lys-
103 in Der f 13 revealed the importance of charged residues as IgE binding epitope. 
Review of several works on IgE epitope mapping also showed that many of the 
important epitope residues mapped are indeed charged residues. This has been 
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confirmed in several major allergens such as Der p 2, Bet v 1, Hev b 6.02, Phl p 5b 
and Par j 1.0101. The content of charged residues also shown to be higher in allergens 
compared to their homologous protein in human, which are presumably non-
allergenic. Although the reason for the preferred charged residues as IgE binding 
epitope is not known, it would be a useful approach to target unique charged residues 
on allergen during epitope mapping and to prepare hypoallergens. 
 
We have here described a systematic way to characterize an allergen starting 
from its structure and sequence information up to the development of a hypoallergen. 
Based on the experimental structure of an allergen, we can predict putative epitope 
residues by using sequence alignment to locate unique surface residues. Alternatively, 
model structures derived from molecular modeling can be used, provided there is a 
highly similar protein structure that can be used as a template. These unique residues 
can be identified by comparing the sequences of allergen and non-allergenic 
homologous protein. Putative epitope residues can then be verified by site directed 
mutagenesis coupled with IgE ELISA experiments to determine the effect on IgE 
binding. With epitope residues removed, the hypoallergen can be tested for PBMC 
proliferation, cytokine release profile and induction of blocking IgG antibodies in 
mouse model.  This systemized routine can be used not only to locate the IgE binding 
site on an allergen, but can also lead to the generation of a hypoallergenic molecules 




5.2 Structure characterization of Blo t 5 
 
Blo t 5 remains as one of the most intriguing allergen from dust mite and less studied 
in terms of its structure and function. With IgE binding prevalence of up to 70%, Blo t 
5 and other group 5 allergens are considered to be the most important allergen after 
the group 1 and group 2 allergens. Although crystallization and x-ray diffraction 
analysis have been reported for Der p 5 (Liaw et al., 1998), surprisingly no x-ray or 
NMR structures have been reported yet for any of the group 5 allergens. With the lack 
of structural information, Blo t 5 is less understood in terms of its allergenicity and 
IgE binding, thus making it difficult to design structure- and epitope-based 
hypoallergen variant . 
 
Blo t 5 has been successfully expressed as a soluble protein in E. coli BL21. 
Blo t 5 exists in a monomeric form as observed by size-exclusion chromatography 
and was purified to high purity using various chromatography methods. The protein is 
extremely soluble and stable even up to 2 mM concentration in 50 mM phosphate pH 
7 buffer for NMR data acquisition. The high solubility enabled us to perform 2D and 
3D NMR experiments and subsequently assigned the backbone chemical shifts of 
almost all HN, NH, Cα and Cβ atoms. However, several amide proton peaks from the 
N-terminal region of the protein were not observable in the 1H-15N HSQC. The 
chemical shift index (CSI) plot has shown that the protein is comprised of 3 α-helices, 
with a long unstructured region consisting of 15 residues in the N-terminal part of the 
protein. The 3 α-helices observed confirms with previous prediction that group 5 
allergens contain 3 α-helices forming a coiled-coil structure (Liaw et al., 2001). 
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5.3 Future direction 
 
Here we have reported a detailed characterization of Der f 13 in terms of its 
solution structure as well as its allergenicity properties. However, the detailed 
function of Der f 13 is still unknown as the functional aspects of ligand or fatty acid 
binding are still not well studied. In the case of human FABPs, all of them have a very 
high specificity in terms of fatty acid binding although most of them share very high 
sequence identity. Several works have been carried out to describe the fatty acid 
binding properties of Blo t 13 but the ligand binding specificity of Der f 13 could be 
different and might be of interest for detail studies. Several isoforms of group 13 
allergens have been identified that share between low to medium sequence similarity 
but can bind to different fatty acids in their protein core. Therefore, it will be 
interesting to study the specificity and affinity of these homologous allergens to 
different fatty acids and their effect on allergenicity. This can be carried out by 
titrating different fatty acids or other ligands to Der f 13 and its isoforms, while 
monitoring the change by CD, fluorescence spectroscopy and heat release in 
isothermal titration calorimeter (ITC).  
 
The mapping of the IgE epitope on Der f 13 has only employed 6 sera from 2 
different sets of population. Thus, the identification of these epitope residues may not 
totally represent epitopes shared by different population or individuals who may react 
to different epitopes. As a result, a more thorough screening of a larger number of 
sera and from different population will give us a clearer picture of whether the 
epitopes are conserved over the global population. Although the residues identified 
seemed to be conserved among all the group 13 allergens such as Blo t 13, Tyr p 13 
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and Lep d 13, the epitopes on these allergens still need to be demonstrated 
experimentally. This can be done by simply mutating the identified epitope residues 
on Blo t 13, Tyr p 13 and Lep d 13 and testing the mutants for IgE binding.  
 
The utilization of 3A mutant as a hypoallergenic molecule against Der f 13 
needs to be further verified by using more animal model experiments. Although the 
patients PBMC showed promising results in both T-cell proliferation and cytokine 
release, 3A mutant still needs to be tested in a real in vivo set up. Therefore, an 
efficient allergy mouse model needs to be set up for Der f 13 to show whether 3A 
mutant can both protect naïve mice from developing allergy against Der f 13 
(prophylactic), and also as a therapeutic method to relieve Der f 13-allergic mice. 
Another concern would be the stimulation of pro-inflammatory TNF-α and GM-CSF 
cytokines by the 3A mutant that might aggravate allergy symptoms. Hence, more 
detailed studies using T-cells assays and mouse model need to be carried out to look 
at the safety aspects of this mutant. These would be crucial to further substantiate the 
potential of 3A mutant as a hypoallergenic molecule. 
 
The concept of charged residues as preferred residues for IgE binding still 
need to be verified as it is only confirmed in couple of epitope mapping studies. Since 
there are countless number of soluble allergenic molecules identified thus far, we can 
design a systematic approach to compare the structure and sequence of allergens 
versus non-allergenic molecules to identify putative epitope residues. This together 
with site-directed mutagenesis and IgE binding studies will enable us to map IgE 
binding epitopes in other allergens, and thus give us more insights on their epitope 
residues profile. It will also be interesting to obtain a crystal structure of the complex 
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formed between an allergen and the IgE Fab fragment and determine whether most of 
the interacting residues are indeed charged residues and what kind of interactions 
(such as electrostatic) would dominate the formation of such complex.  
 
The solution structure of Blo t 5 will be further determined using NMR 
spectroscopy to obtain a final high-resolution structure of the allergen. Although the 
boundaries of the secondary structures have been determined for Blo t 5, a final 
tertiary structure will be much desired to enable us to fully understand the structural 
features of the protein that gave rise to its allergenicity. The assembly of the coiled-
coil structure with the 3 α-helices will be of extreme interest and may give us some 
clue of what role this protein might play in the dust mite. The final structure of the 
Blo t 5 can be used to search against the structure database for protein structures that 
have similar folds. IgE binding epitope will also be mapped by using site-directed 
mutagenesis studies coupled with ELISA experiments. The identification of these 
epitope residues might further strengthen our hypothesis that charged residues are 
preferred residues for IgE binding. Multiple mutations or deletion mutations can be 
carried out to create a hypoallergen, which is of particular interest for immunotherapy 
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Recipe for M9 medium 
 
To 773 ml of sterile water, add the following: 
  200 ml  5X M9 
  2 ml   1M MgSO4 
  5 ml  20% Glucose 
  0.1 ml  1M CaCl2 
  4 ml  0.25 g/ml NH4Cl 
  1 ml  0.1 g/ml Ampicillin 
  1 ml  Kanamycin 
  1 ml  Tetracycline 
 
Composition: 
1. 5X M9  
30 g  Na2HPO4 
15 g  KH2PO4 
2.5 g  NaCl 
Add water to 1L 
(Autoclave) 
 
2. 0.25 g/ml NH4Cl   
50 g NH4Cl, add water to 200 ml 
(Autoclave, or filter-sterilize for 15N) 
 
3. 20% Glucose    
40 g Glucose, add water to 200 ml 
(Autoclave or filter-sterilize for 13C) 
 
4. 1M MgSO4 
19.72 g MgSO4, add water to 80 ml 
(Autoclave) 
 
5 1M CaCl2 
11.76 g CaCl2, add water to 80 ml 
(Autoclave) 
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Appendix II  
 
Buffers for Ni-NTA Affinity Chromatography 
 
• Nickel binding buffer 
 5 mM  Immidazole 
 0.5 M  NaCl 
 20 mM Tris pH 7.9 
 
• Elution Buffer 
 0.5 M  Immidazole 
 0.5 M  NaCl 
 20 mM Tris pH 7.9 
 
• Strip Buffer 
 100 mM EDTA pH 8.0 
 0.5 M  NaCl 
 20 mM Tris pH 7.9 
 
• Ni-Charge buffer 
50 mM NiSO4 
 
Buffers for Glutathione-Sepharose Chromatography 
 
• Phosphate Buffer Saline (PBS) 
140 mM  NaCl 
  2.7 mM KCl 
  10 mM Na2HPO4 
  1.8 mM KH2PO4 
 
• GST Elution Buffer 
  50 mM Tris-Cl pH 7.9 
  10 mM L-Gluthathione (reduced) 
 
• Column Regeneration Buffer 1 
  0.1 M  Tris-Cl pH 8.5 
  0.5 M   NaCl 
 
• Column Regeneration Buffer 2 
  0.1 M  Sodium acetate pH 4.5 
  0.5 M  NaCl 
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Appendix III 
Recipe for SDS-PAGE 
 
 15% Separating Gel 4% Stacking Gel 
30% Acrylamide/0.8% Bis 3.5 ml 0.4 ml 
Resolving Buffer 1.75 ml - 
Stacking Buffer - 0.75 ml 
10% SDS 70 µl 30 µl 
Water 1.68 ml 1.8 ml 
10% Ammonium Persulphate 42 µl 30 µl 
TEMED 4.2 µl 3 µl 
 
1. Acrylamide solution (30%, 0.8 % Bis) 
2. Resolving gel buffer: 1.5 M Tris, pH 8.8 
For 200 ml, 36.3 g of Tris adjust to pH 8.8 with HCl 
3. Stacking gel buffer: 0.5 M Tris, pH 6.8 
For 200 ml, 12.1 g Tris, adjust to pH 6.8 with HCl 
4. 10% Ammonium persulphate: 1 g Ammonium persulphate in 10 ml water 
5. 10X Tank buffer: for 2 liters 
60 g  Tris base 
288g Glycine 
200 ml 10% SDS solution 
water to 2 liters 
8. 2X SDS gel sample buffer: for 50 ml 
5 ml  Glycerol 
6.25 ml  0.5 M Tris pH 6.8 
12.5 ml 10% SDS 
2.5 ml   β-mercaptoethanol 
0.01 g  Bromophenol blue 
water to 50 ml 
9. Stain stock: 1% Coomassie Brilliant Blue G (Stir and filter) 
10. Destaining solution: for 2 liters 
140 ml  Acetic acid 
100 ml  Methanol 
water to 2 liters 
 
 
 
